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ABSTRACT OF THESIS

DESIGN, SYNTHESIS, AND ANTICANCER ACTIVITY OF RUTHENIUM COMPLEXES
Ruthenium complexes show promise as light activated photodynamic therapy (PDT)
prodrugs. Strained octahedral complexes were synthesized that produce a cytotoxic
species upon light activation. pUC19 DNA damage in vitro experiments were carried
out to determine the type of damage observed. In vivo cell experiments were carried
out on the non‐small lung cancer A549 cell line to determine the phototherapeutic
window of the synthesized complexes. One mechanism of drug resistance via
elevated levels of glutathione was addressed through in vitro binding studies carried
out with UV‐Vis spectroscopy and in vivo glutathione titrations in the A549 cell line.
Several complexes were shown to be potential PDT agents with light‐activated
activities greater than cisplatin and 10‐100 fold lower dark toxicities.
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Chapter 1: Introduction
In 2008, 12.7 million new patients were diagnosed with cancer and 7.6
million patients died from cancer related issues.1 The disease does not discriminate
between societies, afflicting economically developed and developing countries
alike.1 The term cancer applies to a broad swath of diseases characterized by the
inability of an abnormal cell to regulate growth, allowing it to potentially form
tumors. Disruption of the regulation of normal tumor suppression genes and
activation of oncogenes lead to this abnormal growth and fast track the
development of the disease. The combination of over expression of cell growth
promoters and increased cellular survival mechanisms allow the abnormal cells to
proliferate.2
Common cancer therapies include surgery, radiotherapy, and chemotherapy.3
Combinations of the three are common based on the location of the cancer, risk
factors, and potential for successful outcomes.4 Chemotherapy involves the use of
antineoplastic drugs to kill cells that divide rapidly. Current drugs in the clinic can
be divided into categories based on their mechanism of action to prevent replication
of rogue cells, and many cause DNA damage leading to apoptosis. Drug categories
include alkylating agents, antimetabolites, anthracyclines, plant alkaloids, and
topoisomerase inhibitors.5,6,7,8,9
Approximately 50% of people undergoing chemotherapy are treated with the
alkylating agent, cisplatin.10 Cisplatin is used to treat a variety of cancers including
testicular, ovarian, head, and neck cancers.11 The drug works by covalently binding
1

to DNA, rendering the cell unable to undergo cellular division. When DNA repair
mechanisms fail to work, apoptosis results.12 Cisplatin and similar platinum
complexes favor the N7 position of pyrimidines and the N3 position of purines
(Figure 1.1).13
Figure 1.1: Base pairs shown numbered and hydrogen bonded

Guanine (G) – Cytosine (C)

Adenine (A) – Thymine (T)

Cisplatin is capable of platinating double stranded DNA through intrastrand
and interstrand mechanisms.14 The majority of cytotoxic interactions arise from the
intrastrand cross‐linking of adjacent purines. Guanosine is preferred over adenosine,
and cisplatin favors intrastrand binding of adjacent guanosines, but will also
coordinate adenosines adjacent to guanosine. Interstrand complexes are lesser
realized and provide similar damage.15 All of these structures distort the DNA
structure and activate cellular DNA damage mechanisms such as the expression of
p53, and apoptosis.16
2

Drug resistance for platinum compound chemotherapy is thought to arise
from many mechanisms, including detoxification by cellular sulfur‐containing
compounds.17 Glutathione is a natural tripeptide found in the cytosol of almost all
cells in concentrations up to 16 mM.18,19,20 The sulfur rich compound is a good ligand
for platinum according to Pearson’s hard soft acid base theory.21 Other sulfur
containing metal detoxification agents such as metallothionein have been found in
similar concentrations in cisplatin‐insensitive cells. These detoxifying agents
interfere with the chemotherapeutic role of platinum compounds and are a
substantial contributor to increased drug resistance.22

Several derivatives of

cisplatin such as oxaliplatin and carboplatin have been synthesized with the goal to
thwart resistance, decrease toxicity and improve activity.23 Figure 1.2 shows several
structures of platinum compounds that are currently in clinical trials and
commercially available for therapeutic use.24,25 These platinum derivatives work
through the same DNA damage mechanism and share dose limiting toxicities and
adverse side effects observed with cisplatin.26 These side effects include
nephrotoxicity, nausea, ototoxicity, and electrolyte disturbance.27

3

Figure 1.2: Current platinum chemotherapeutic agents
Trade Name

Complex Structure

carboplatin

oxaliplatin

AMD473

JM216 (satraplatin)

Despite the toxicity and side effects of cisplatin and other platinum
derivatives, these drugs (in combination with other therapeutics) are quit successful
in treating a variety of cancers.28,29,30 Building on this success, other metal centered
drugs have been synthesized in an attempt to minimize adverse effects.31,32 Several
metals including ruthenium, rhenium, and osmium have been investigated as
possible chemotherapeutics.33 Ruthenium compounds are a potential alternative to
their platinum counterparts due to the decreased toxicity and variable oxidation
states accessible under physiological conditions.34 Two ruthenium drugs, NAMI‐A
and KP1019 are currently in clinical trials (Figure 1.3).35,36
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Figure 1.3: Ruthenium drugs currently in clinical trials
Trade Name

Complex Structure

NAMI‐A

KP1019

NAMI‐A is an arene Ru(III) drug that is used for treatment of non‐small cell
lung cancer through reducing metastases weight without affecting the primary
tumor. It is well tolerated by patients in clinical studies.37 KP1019 is activated by
reduction from RuIII to RuII in hypoxic tumor tissues by reducing sulfur rich
biomolecules such as glutathione.34 KP1019 has been used in clinical trials for
colorectal cancer and is also well tolerated in patients. 36
Ruthenium polypyridyl complexes have also been investigated for their
potential chemotherapeutic qualities. These complexes are well studied, and
derivatives of the ruthenium polypyridyl complex have been synthesized to target
DNA.34,38 Due to the rich synthetic nature of ruthenium, several complexes containing
ligands with high DNA affinity have been synthesized. The groove binding and
5

metallo‐intercalating ability of 1,10 phenanthroline (phen) and dipyrido [3,2‐f: 2’,
3’‐h‐quinoxaline] (dpq) (see Table 2.1) are well known.39
NAMI‐A and KP1019 provide of novel chemotherapeutics outside of cisplatin
and display how transition metals can provide several interesting complex
structures capable of leading to apoptosis. Alternatively, the DNA binding
ruthenium compounds in the literature provides an alternative to platinum drugs
with a non‐covalent mechanism of DNA interactions. The problem with all these
approaches, however, is the lack of specificity, as these drugs do not discriminate
between healthy and cancerous cells.
To improve selectivity and decrease toxicity, photoactive complexes can
increase the therapeutic window of antitumor drugs. For this reason photodynamic
therapy (PDT) can be used to treat localized tumors with laser‐based fiber‐optic
devices.40 PDT is used to treat a variety of cancers accessible with a light source
including lung, superficial gastric, cervical, bladder, head, and neck.

Patients

utilizing PDT benefit from the relatively non‐invasiveness of the treatment that can
often be administered in an outpatient setting.41 This targeted treatment reduces
the side effects associated with traditional chemotherapy and because dose‐limiting
toxicity is nonexistent, toxicity is only induced in the targeted tissues when light
activated. Repeated treatments are therefore possible. Photofrin is clinically used to
treat early and advanced stage lung cancer and Foscan is used in treatment of
palliative head and neck cancer (see Figure 1.4).42,43
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Figure 1.4: Photosensitizers available for chemotherapeutic use
Trade Name

Complex Structure

Photofrin

Foscan

Levulan
Metvix

Topical photosensitizers such as Levulan and Metvix are biosynthetic
precursors to photofrin, and are used in the clinic to treat actinic keratosis.44 The
benefit of these drugs lies in the mechanism of action. These catalytic compounds
form singlet oxygen as they absorb the light energy, becoming excited and
transferring the energy to triplet excited oxygen (3O2). This energy transfer causes
one of the unpaired valence electrons to flip, fueling the production of the cytotoxic
7

singlet oxygen (1O2).45 Added selectivity arises from the inability of the highly
reactive, short‐lived species to diffuse across more than one membrane, causing
minimal damage to normal tissue.46 The drawback to the singlet oxygen mechanism
arises from the apoxic nature of malignant and more aggressive cancer cells.
Photoactivatable metal complexes have been investigated as alternative PDT
therapeutics to porphyrin based photosensitizers. Photoactive octahedral PtIV
complexes have been investigated due to their ability when light activated to be
reduced to their cytotoxic PtII species. These complexes show better aqueous
solubility and increased therapeutic indexes with reduced toxicity.33 One drawback,
however, is the need to activate the PtIV species with high energy UV light.
Polypyridyl ruthenium complexes have also been investigated due to the fact that
various structures can be readily synthesized and possess tunable absorption
properties.47 Long wavelength light is desired in PDT due to its increased tissue
penetration. Low energy transitions that absorb at longer wavelengths in the MLCT
(metal‐to‐ligand‐charge transfer) region are an important attribute in the design of
the metal‐based compounds. Various groups have developed several metal
complexes that display light induced cytotoxicity through oxygen independent
mechanisms.48,49
Due to the rich nature of the synthetic chemistry associated with ruthenium
compounds, and the promising clinical results of NAMI‐1, KP1019 and
photoactivatable platinum complexes, alternative light‐active ruthenium complexes
hold promise as potential anti‐cancer agents. The goal of this research project is to
8

produce novel ruthenium compounds that display low to no activity in the dark in
both in vivo and in vitro experiments, but can be turned on by light to become potent
cytotoxic agents. We aim to make efficient light activated complexes that display
high DNA binding, crosslinking, or other forms of DNA damage, resulting in toxicity
in cancer cells. The primary factor considered for light‐activated agents is the ratio
of the activity in light vs. in the dark, which is termed the phototherapeutic ratio.
This is a direct measurement of the therapeutic window for PDT.

Several

compounds have been synthesized, characterized, and screened in cancer cells for
beneficial anti‐tumor behavior in this work. The goals defined at the onset of the
project included light‐activated potencies comparable to cisplatin, and a 10‐fold
phototherapeutic ratio, allowing for the potential of significant reduction in side‐
effects in future clinical applications. The progress towards achieving these goals is
described in the following chapters. The thesis is divided into the following
chapters: Design, synthesis, in vitro and in vivo characterization of the complexes
synthesized for this thesis. Several scientists contributed to this work and are
appropriately cited for the work they contributed.
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Chapter 2: Design and Synthesis

1: Design

The photochemistry of ruthenium polypyridyl complexes such as
[Ru(bpy)3]2+ have been extensively studied.1 The unique combination of chemical
stability, redox properties, excited‐state reactivity, luminescence emission, and
excited‐state lifetime of [Ru(bpy)3]2+ and its derivatives has garnered the attention
of researchers across multiple disciplines.2Ru(II) polypyridyl complexes play key
roles in multiple research areas such as photophysics, photocatalysis, and electron
and energy transfer.1The photochemical and photophysical nature of these
compounds is of interest to our group and will be the main focus of this chapter. The
hypothesis of this project is that light‐activated Ru(II) complexes can be designed to
eject ligands upon irradiation, producing ligand deficient systems that will react
with and crosslink DNA, like cisplatin. The application of these systems is for the
development of photo‐responsive chemotherapeutic agents. The key feature that
controls this photochemical reaction is intramolecular strain, generating distorted
Ru(II) complexes that undergo photochemical reactions with low energy, visible
light.
Unstrained Ru(II) polypyridine complexes such as [Ru(bpy)3]2+ contain
ligands with  donor orbitals that are localized on the nitrogen atoms and  donor
and * acceptor orbitals delocalized on the aromatic rings. Ru(II) polypyridyl
complexes are typically orange to red, due to their absorption of visible light. The
10

absorption spectrum of [Ru(bpy)3]2+ is shown in Figure 2.1awith the electronic
transitions assigned.
Figure 2.1: Electronic absorption spectrum of a) [Ru(bpy)3]2+ and b) GL002
[Ru(bpy)2‐6,6’‐dmbpy]2+in dH2O.

The intense band at 285nm results from spin‐allowed, ligand centered (LC) 
to * transitions. The intense metal‐to‐ligand charge transfer (MLCT) bands at 240
and 450nm result from spin allowed d to * transitions. The less intense shoulder
bands at 320 and 340nm result from metal‐centered (MC), M to Mtransitions.
Figure 2.2a shows a simplifiedJablonski diagramfor excitation of an electron
by following absorption of a photon with promotion from the ground state to the
1MLCT.

11

Figure 2.2: Electronic transitions of (a) unstrained d6 Ru(II) complexes and (b)
strained d6 Ru(II) complexes.
(a)

(b)

Once the 1MLCT excited state is populated, intersystem crossing efficiently funnels
electrons to the lower 3MLCT excited state.1Radiative relaxationfrom the 3MLCT to
the ground state of [Ru(bpy)3]2+ produces an intense emission band at 610nm and is
shown in Figure 2.3a.
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Figure 2.3: Emission profile of a) [Ru(bpy)3]2+ and b) [Ru(bpy)2dmbpy]2+.

Long luminescent lifetimes of 800 ns are reported for the transition from the
3MLCT

excited state to ground state with a quantum efficiency of ~0.06.1Population

of the 3MC state for [Ru(bpy)3]2+is inefficient, producing a poor quantum yield for
photodecomposition on the order of 10‐5‐10‐2.1For unstrained d6 Ru(II) complexes
such as [Ru(bpy)3]2+, population of the 3MC state is inefficient due to the large
energy gap between the 3MLCT and 3MC, resulting mainly in emission from the
3MLCT

state.
Absorption profiles similar to [Ru(bpy)3]2+ are observed in strained d6 Ru(II)

polypyridine complexes. The emission profile of the complex Ru(bpy)2‐6,6’‐dmbpy,
GL002, is shown in Figure 2.3b. In contrast to standard octahedral Ru(II) complexes,
strained complexes undergo fast radiationless deactivation to the ground state. This
occurs through ligand dissociation reactions when the 3MC state is lowered in
energy so that it can be accessed thermally from the 3MLCT state. Synthesis of
sterically strained ruthenium complexes decreases the 3MLCT to 3MC energy gap,
allowing population of the 3MC excited state, resulting in cleavage of the Ru‐N bond.
Figure 2.2b shows this in analtered Jablonski diagram, and depicts how electrons
13

are successfully shuttled to the 3MC excited state orbitals. The efficient population of
the 3MC state is manifest in the decreased intensity of the emission spectra shown in
Figure 2.3b.
Upon photo‐excitation of the complex, a bond is broken to a bipyrine ligand,
and a monodentate bipyridine intermediate with a ruthenium that is
pentacoordinated forms. In the presence of excess electron donating ligands such as
chloride ions or solvent molecules, new bonds to the ruthenium can form. At this
point, are‐coordination process can occur, reforming the Ru‐N bond or alternatively,
the single remaining bond to the bipyridine ligand can be broken, forming a Ru(II)
complex with two chloride or two solvent ligands. The re‐coordination process is
possible with unstrained octahedral complexes such as [Ru(bpy)3]2+,while ligand
loss prevails in the model compound GL002, due to the steric clash of the methyl
groups.
Photolabile model complexes with the Ru(bpy)2 backbone containing
sterically crowding ligands such as 6,6’‐dimethyl‐2,2’‐bipyridinehave been prepared
to promote the population of the 3MC excited state, leading to the complete
dissociation of the ligand. This generates the ligand deficient, bis‐bipyridine Ru(II)
complexcapable of cross‐linking DNA. Several photo‐active complexes utilizing the
Ru(bpy)2 backbone have been synthesized including GL002, 003, 006, 007, 008, 010,
and 014 (see Table 2.2). The rate at which the complexes photo‐dissociate can be
tuned through the choice of ligands. The complex GL002 has fast photoejection
kinetics (t1/2=1.9 minutes, see Table 3.1) due to the free rotation about the 2,2’‐
14

carbon‐carbon bond of 6,6’‐dimethyl‐2,2’‐bipyridine. In contrast, addition of rigid
ligands to the Ru(bpy)2backbone slows the ejection process. For example, when the
2,9’‐dimethyl‐1,10‐phenanthroline ligand is incorporated(see GL007, Figure 2.5),
at1/2 of 112.8minutes is obtained, as shown in Table 3.1. This is attributed to the
ligands’ ability to re‐coordinate the metal, due to its rigid chelating structure.
The DNA affinity of the complexes can also be tuned through the addition of
intercalating ligands such as dpq (dipyrido[3,2‐f:2’,3’‐h‐quinoxaline]) and dppz
(dipyrid0[3,2‐2',3'‐c]phenazine) (see Table 2.1). These planar ligands are known to
intercalate into the base stack of DNA.3 Complexes GL003, 009, 010, 021 and 039
were synthesized to test if photoejecting complexes with DNA intercalating ligands
are more potent than compounds with lower DNA affinity. Unstrained complexes
GL009 and 021 contain dpq and dppz ligands that display bindingto pUC19 DNAin
vitro, as discussed in Chapter 4. The photoejectable analogues of these complexes
GL003, 010, and 039 were synthesized to explore their biological activity in vitro
and in vivo.
Complexes with different overall charge states and alterative backbones have
been prepared to determine how these factors change the invitro and invivo
experimental results. Ruthenium compounds with different overall charges such as
GL005 (overall charge of ‐2) and 008 (overall charge of 0) display different cytotoxic
properties. Decreased affinity to the negatively charged DNA backbone is thought to
account for some of the differences in biological activities.Complexes with different
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Ru(dmphen)2 backbones have also synthesized. GL018, 019, 022, 023, and 039 are
examples of these complexes (see Table 2.2).
Complexes GL018 and 019 contain hydroxyquinoline ligands that are known
to be cytotoxic.4These complexes were designed to test the hypothesis that
complexes could be generated that would create two active species – the ligand
deficient Ru(II) complex, and the liberated ligand. Studies have shown that
hydroxyquinoline and its derivatives have anti‐proliferative and cytotoxic effects in
leukemia cells lines.5 They inhibit RNA synthesis in E. coli bacteria and iron
complexes containing these ligands have been shown to be effective in the U937,
K562, ML2, and HL60 cell lines.6 In addition, hydroxyquinoline derivatives chelate
copper, and acts as angiogenesis and proteasome inhibitors in prostate cancer cell lines.7
An effort has been made to produce ruthenium complexes that absorb at
longer wavelengths, as longer wavelength (lower energy) light can penetrate deeper
into tissues. Thiswould provide access to tumors previously unreachable via
photodynamic therapy. Addition of the biquinoline (biq) ligand to the Ru(phen)2
backbone (see Table 2.2) produces a 60 nm red shift in the UV/Vis profile of
complex GL011 (see Figure 3.2). Alternatively, cyclometallating ligands 2‐
phenylpyridine and 7,8‐benzoquinoline coupled with the Ru(bpy)2 backbone
produced complexes GL034 and 035 (see Table 2.2).These cyclometallated systems
display 100 nm red shifts in their corresponding UV‐Vis profiles (Figure 3.1).
Unfortunately these compounds do not eject as they are unstrained, and are unable
to populate the 3MC excited state. In the future, strained and photo‐active analogues
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of these systems should be synthesized to determine their in vitro and in vivo
properties. Finally, oxygen containing hydroxyquinoline ligands also act to lower the
energy of the MLCT excited state, potentially red-shifting the absorption of the
complexes further into the PDT therapeutic window. Derivatives of complexes
containing the backbones presented in this work with different quinolines should be
synthesized to evaluate their phototherapeutic ratio.

2. Synthesis
Several scientists contributed to the synthesis chapter, including Dr. Edith Glazer,
Erin Wachter, and Emily Hall.
Several ruthenium complexes were synthesized to gain an understanding of
how the structural characteristics affect the photophysics and photochemistry of the
complexes and theirin vitroactivities with pUC19 DNA (Chapter 4) and in
vivopotencies in the A549 cell line (Chapter 5).

Complexes that produce an

activated species upon exposure to light were prepared to observe differences in
light and dark activity with DNA.
The general preparation of these complexes begins with the synthesis ofthe
ligands used (Figure 2.4) and then generating the Ru(L)2Cl2 starting material (see
Figure 2.5). The synthetic nature of ruthenium (see Chapter 1) allows efficient
combinatorial design. Mono ligands ejected from synthesized complexes upon light
activation that show toxicity can be incorporated into the bis‐Ru backbone resulting
in massive libraries that can be screened against the cell line. Several ligands
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utilized in this thesis were synthesized to test how structural planarity of the ligand
effect the photoejection kinetics, in vitro, and in vivo results. The general synthetic
pathway to produce the ligand(s) is shown in Figure 2.4. These are good reactions,
with yields of 60% or greater.8,9
Figure 2.4: General synthesis of extended polyaromatic ligands

Once the appropriate ligands are synthesized, the desired ruthenium complex
starting material can be produced with the reaction scheme shown in Figure 2.5 in
good yields.10
Figure 2.5: Synthesis of the ruthenium starting material with two bidentate ligands

With the synthesized starting materials, modular, high yielding complexes can be
produced.11 The reactions and subsequent purification are carried out in diminished
light conditions to prevent photo‐degradation of the complexes.
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Figure 2.6: Addition of a third ligand to produce efficient phototherapeutic agents

General preparation of complexes with Ru(L)2Cl2 backbone:
A solution of RuCl3 (3.8 mmol, 1 g), free ligand L (7.6mmol, variable g)
LiCl(57 mmol, 2.4 g) and ascorbic acid (4.2 mmol, 0.74 g) were added to 25 mL dry
DMF and refluxed at 150oC for 12 hours. The solution was allowed to cool to room
temperature, and the purple product was precipitated with a mixture of cold
acetone/ether (50 mL each). The precipitate was collected by vacuum filtration and
washed with acetone/ether and dried under vacuum. The yield of Ru(phen)2Cl2 is
65% and Ru(dmphen)2Cl2 is 71%.
General preparation of complexes with Ru(L)2L’‐2PF6:
A solution of 0.38mmol Ru(L)2Cl2 (0.1 g) and 0.42 mmol L’(variable g) was
added to 4 mL ethylene glycol in a pressure tube and heated at 150 oC for ~4 hours.
The solution was allowed to cool and poured into 50 mL of dH2O. A saturated
solution of aq. KPF6 was added to precipitate the complex as the PF6 salt. The
precipitate was collected by vacuum filtration and washed with water (50 mL) and
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ether (50 mL) and dried under vacuum. A non‐emissive, dim spot on thin layer
chromatography (TLC) (0.1% saturated KNO3/20%H2O/80%MeCN on silica plates)
is evidence that the strained complex has formed (see Figure 2.2b).
For unstrained complexes, the starting materials were added to 50:50 water:
ethanol and refluxed at 100 oC for 4 hours. The solution was poured into ~50 mL
dH2O and the excess ligand was extracted with methylene chloride. Saturated aq.
KPF6 was added and the PF6 salt was extracted in methylene chloride. The layer was
dried over magnesium sulfate, filtered and concentrated under reduced pressure. A
bright, emissive spot observed using TLC conditions described above is evidence
that the unstrained complex has formed (see Figure 2.2a). Similar purification of the
complexes was carried out using flash chromatography. Complexes were loaded
onto the column in acetonitrile and eluted with a ramping gradient of 0.1%
saturated KNO3/20%H2O/80%MeCN. The synthesized complexes typically elute at
9% dH2O. Solvent was removed under reduced pressure and reconstituted in 25 mL
of dH2O. A saturated aq. solution of KPF6 was added, and the metal complex was
extracted into methylene chloride. Removal of the solvent under reduced pressure
gave pure PF6 complex salts.
General procedure to counter‐ion exchange to produce water‐soluble complex salts:
Saturated tetra‐n‐butyl ammonium chloride (1 g in 5 mL dry acetone) was
added to the PF6 complex salts dissolved in minimal acetone. The resulting
precipitate was filtered in a long stem hersch funnel packed with glass wool. The
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precipitate was washed with acetone and eluted with acetonitrile. The solvent
was removed under reduced pressure to yield the water soluble Ru(L)2L’-2Cl salt.
Synthesis of 1,10‐phenanthroline‐5,6‐dione (phendione):12
4 g (20 mmol) 1,10‐phenanthroline and 3.6 g (30 mmol) KBr was added to a
125 mL round bottom flask and chilled in an ice bath. 1.5:1 mixture of concentrated
H2SO4: HNO3(40/20 mL respectively) were added dropwise to the flask. Caution:
The reaction is very exothermic and evolves bromine gas. The reaction should be
carried out in the hood with the hood sash at a minimum height. Care should be taken
handling the concentrated acids. Following addition of the acid mixture, the solution
was refluxed for 3 hours at 100 oC. The solution was removed from heat and allowed
to cool to room temperature. The bright orange solution was poured over 500 mL of
ice in a large beaker and the flask was rinsed with ice and was slowly neutralized
with NaOH pellets producing a milky, dark yellow solution. Care should be taken to
not overshoot the neutral pH producing a basic solution. At basic pH’s, the solution
turns green and result in decreased yields. The product was extracted in CHCL3 and
dried over magnesium sulfate producing a clear yellow solution that was
concentrated using rotary evaporation and dried under vacuum. The methylated
analogue

2,9‐dimethyl‐1,10‐phenanthroline‐5,6‐dione

(dmphendione)

was

prepared in a similar method using the 2,9‐dimethyl‐1,10‐phenanthroline (dmphen)
starting material.
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Synthesis of dipyrido[3,2‐f:2’,3’‐h‐quinoxaline (dpq):13
Caution: Phendione is a flocculent solid and is a mucous irritant. To reduce
exposure, tare the reaction flask and transfer the material in the fume hood. 1 g (47.5
mmol) phendione and 350 mL ethanol were added to a 500 mL round bottom flask.
0.49 mL (d=0.899 gcm‐3,71 mmol)1,2‐diaminoethane was added to the flask
(solution golden brown) and heated at 40 oC for 2 hours. The reaction was
monitored by TLC using 10% methanol in methylene chloride. The reaction was
removed from heat and allowed to stir for 5 hours at room temperature producing a
golden, brown solution. The solution was reduced by rotary evaporation to yield a
white solid that was recrystallized from boiling methanol to yield an off‐white solid.
The dimethyl analogue of this ligand was prepared in a similar method using the
dmphendione starting material with similar yields.
Synthesis of dipyrid0[3,2‐~:2',3'‐c]phenazine (dppz):13‐14
1 g (47.5 mmol) phendione and 0.77 g (71 mmol) 1,2‐phenylene‐diamine
were added to a 120mL pressure tube with 1:2 EtOH: dH2O (30 mL: 60 mL). The
pressure tube was placed in an oil bath at 180oC and stirred for 3 hours producing a
brownish‐orange solution. Caution: A blast shield should be utilized with the hood
sash at minimum height to reduce explosion hazards. The reaction tube was removed
from heat and allowed to cool producing a feathery, yellow solid that was collected
by vacuum filtration. Additional crops of precipitate were obtained upon cooling the
mother liquor and were collected by vacuum filtration. Similar TLC conditions used
in the synthesis of the dpq ligand were used to monitor the reaction. The dimethyl
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analogue (dmdppz) of this ligand was prepared in a similar method using the
dmphendione starting material with similar yields.
Spectroscopic Characterization of Synthesized Ligands:
1,10‐phenanthroline‐5,6‐dione (phendione):
Yield: 3.8 g (90%).1H NMR (CDCL3, 400 MHz): 1H NMR (CDCl3):δ 9.05 (d, J=4.76 Hz,
2H), 8.43 (d, J=7.51 Hz, 2H), 7.53 (t, J=6.23, 2H).
2,9‐dimethyl‐1,10‐phenanthroline‐5,6‐dione (dmphendione):
Yield: 1.9 g (75%). 1H NMR (CDCL3, 400 MHz): 1H NMR (CDCl3):δ 8.36 (d, J=8.06 Hz,
2H), 7.40 (d, J=7.76 Hz, 2H), 2.83 (s, 3H).
Dipyrido[3,2‐f:2’,3’‐h‐quinoxaline (dpq):
Yield: 1.03 g (92.8%).1H NMR (CDCL3, 400 MHz): 1H NMR (CDCl3):δ9.47 (d, J=8.24
Hz, 2H), 9.27 (d, J=4.40 Hz, 2H), 8.97 (s, 2H), 7.78 (td, 6.22 Hz, 4.40 Hz, 2H).
Dimethyl‐dipyrido[3,2‐f:2’,3’‐h‐quinoxaline (dmdpq):
Yield: 1.1 g (88%). 1H NMR (CDCL3, 400 MHz): 1H NMR (CDCl3):δ 9.37 (d, J=8.24 Hz,
2H), 8.93 (s, 2H), 7.65 (d, J=8.42 Hz, 2H), 3.07 (s, 6H).
Dipyrido[3,2‐f:2',3'‐c]phenazine (dppz):
Yield: 872 mg (65%). 1H NMR (CDCL3, 400 MHz): 1H NMR (CDCl3):δ 9.17 (d, J=8.15
Hz, 2H), 8.90 (d, J=4.49 Hz, 2H), 8.01 (d, J=6.59 Hz, 2H), 7.78 (d, 6.50 Hz, 2H), 7.61
(td, J=6.23 Hz, 6.41 Hz, 2H). ESI MS calcd for C18H10N4[M]+282.1, found 283 [M]+.
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Dimethyl‐dipyrid0[3,2‐~:2',3'‐c]phenazine (dmdppz):
Yield: 0.9 g (65%). 1H NMR (CDCL3, 400 MHz): 1H NMR (CDCl3):9.50 (d, J=8.24 Hz,
2H), 8.31 (d, J=6.59 Hz, 2H), 7.81 (d, J=6.50 Hz, 2H), 7.63 (d, J=8.24 Hz, 2H), 2.97 (s,
6H). ). ESI MS calcd for C20H14N4[M]+310.12, found 311 [M]+.
Spectroscopic Characterization of Synthesized Ruthenium Complexes:
Complexes GL005, GL008, and GL013 are sulfonate or carboxylate containing
complexes that could not be isolated from water due to solubility. Because of this,
NMR data could not be obtained. ESI‐MS data are given for each complex.
Ru(bpy)2dmbpy, GL002:
Yield: 297 mg (87%). 1H NMR (CD3CN, 400 MHz):  8.48 (d, J=8.24 Hz, 2H), 8.40 (d,
J=8.42 Hz, 2H), 8.27 (d, J=8.42 Hz, 2H), 8.08 (td, J=8.06, 1.65 Hz, 2H), 7.96‐7.90 (m,
6H), 7.62 (d, J=5.31 Hz, 2H), 7.46 (td, J=5.86, 1.65 Hz, 2H), 7.29 (d, J=6.59 Hz, 2H),
7.21 (td, J=7.32, 1.47 Hz, 2H), 2.14 (s, 6H).

13C

NMR (CD3CN):  166.69, 159.91,

158.68, 158.44, 154.06, 152.90, 139.22, 138.85, 138.81, 129.18, 128.49, 128.29,
125.47, 125.39, 123.18, 25.62. ESI MS calcd for C32H28N6Ru [M]+ 598.1, [M]2+ 299;
found 598.3 [M]+, 299.1 [M]2+. Purity by HPLC: 98.8% by area.UV/Vis (MeCN) ε: 247
nm (23100), 289 (72500), 452 (13900).
Ru(bpy)2dmdpq, GL003:
Yield: 284 mg (77%).1H NMR (CD3CN, 400 MHz): 9.51 (d, J = 8.4 Hz, 2H), 9.17 (s,
2H), 8.5 (dd, J = 8.24, 8.24 Hz, 4H), 8.02 (quin, J = 7.69, 4H), 7.72‐7.80 (m, 6H), 7.29
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(t, J = 6.68, 4H), 2.19 (s, 6H).

13C

NMR (CD3CN):  169.63, 158.65, 158.52, 154.14,

152.98, 151.44, 147.69, 139.84, 139.05, 138.84, 134.96, 129.47 129.04, 128.53,
128.49, 125.62, 125.54, 26.51. ESI MS calcd for C36H28N8Ru [M]+ 674.1, [M]2+ 337;
found 673.1 [M]+, 336.9 [M]2+. Purity by HPLC: 95.1% by area.UV/Vis (MeCN) ε: 256
nm (49700), 289 (65100), 452 (13100).
Ru(bpy)2phen, GL004:
Prepared per literature procedure.15 1H NMR (CD3CN, 400 MHz): 8.41 (d, J= 8.02 Hz,
2H), 8.36 (d, J=8.2 Hz, 2H), 8.01 (s, 2H), 7.91 (t, J= 7.8 Hz, 2H), 7.78 (dt, J=10.7 Hz, 5.3
Hz, 4H), 7.53 (t, J= 6.60, 2H), 7.45 (d, J= 5.0, 2H), 7.25 (t, J= 6.3, 2H), 7.01 (t, J=6.25,
2H).

13C

NMR (CD3CN): 157.23, 157.02, 151.96, 151.65, 151.61, 147.49, 137.47,

137.36, 136.55, 130.75, 127.81, 126.97, 126.93, 126.93, 126.80, 125.46, 123.88,
123.82. Additional 13C peaks due to concentration dependent molecular aggregation
through π‐stacking in solution.16ESI MS calcd for C32H24N6Ru [M]2+ 287.01, found
287 [M]2+. Purity by HPLC: 98.1% by area.
Ru(bpds)2dmbpy, GL005:
ESI MS calcd for C60H40N6O12RuS4 [M]2‐633.03, found 632.6 [M]2+.
Ru(bpy)2‐3,3’‐dmbpy, GL006
Yield: 150 mg (90%).

1H

NMR (CD3CN, 400 MHz): 8.50 (d, J=7.6 Hz, 4H), 8.05 (m,

4H), 7.83 (d, J=7.8 Hz, 4H), 7.70 (d, J=5.6 Hz, 2H), 7.59 (d, J= 5.1 Hz, 2H), 7.39 (m, 4H),
7.26 (s, 2H), 2.47 (s, 6H).

13C

NMR (CD3CN):  148.28, 158.159, 158.053, 153.081,

150.606, 141.89, 138.71, 138.67, 137.87, 128.50, 128.34, 126.80, 125.28, 125.19,
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21.38. ESI MS calcd for C32H28N6Ru [M]2+ 299.07, found 299.1 [M]2+. Purity by HPLC:
98.8% by area. UV/Vis (MeCN) ε:240 nm (26500), 289 (71600), 453 (13500)
Ru(bpy)2dmphen, GL007
Yield: 160 mg (95%). 1H NMR (CD3CN, 400 MHz): 1H NMR (CD3CN):  8.57 (d, J = 8.0
Hz, 2H), 8.50 (d, J = 7.8 Hz, 2H), 8.09 (dt, J = 8.0, 1.4 Hz, 2H), 8.05 (s, 2H), 8.02 (td, J =
8.2, 1.5 Hz, 2H), 7.82 (d, J = 5.8 Hz, 2H), 7.77 (d, J = 5.8 Hz, 2H), 7.78‐5.59 (m, 4H),
7.34 (td, J = 9.0, 1.4 Hz, 2H), 7.31 (td, J = 9.0, 1.4 Hz, 2H), 2.0 (s, 6H).

13C

NMR

(CD3CN):  167.50, 158.75, 158.4, 1554.01, 153.96, 152.82, 152.86, 150.53, 150.34,
138.90, 138.74, 136.87, 130.79, 130.62, 130.14, 128.94, 1218.86, 128.53, 128.48,
128.41, 128.34, 125.87, 125.59, 125.49, 26.49.16ESI MS calcd for C34H28N6Ru [M]‐
+622.14,

found [M]+621.2, [M]2+311.1. Purity by HPLC: 99.9% by area. UV/Vis

(MeCN) ε:287 nm (60200), 452 (12800).
Ru(bpy)2bcds, GL008:
ESI MS calcd for C46H34N6O6RuS2 [M]+ 932.10, [M]2+466.1 found [M]+ 955.3 (+Na),
[M]2+ 488.9 (+Na).
Ru(bpy)2dppz, GL009:
Yield: 133 mg (35%). 1H NMR (CD3CN, 400 MHz): 1H NMR (CD3CN):  9.32 (dd, J =
8.24, 1.5 Hz, 2H), 8.60 (t, J = 9.18 Hz, 4H), 8.20‐8.13 (m, 6H), 8.06 (t, J = 7.69 Hz, 2H),
7.98‐7.91 (m, 4H), 7.84‐7.77 (m, 4H), 7.52 (t, J = 6.32 Hz, 2H), 7.36 (t, J = 6.87 Hz, 2H).
13C

NMR (CD3CN):  158.27, 158.07, 154.77, 153.20, 153.06, 151.56, 143.84, 141.12,

139.06, 138.97, 134.58, 133.62, 1311.95, 130.71, 128.70, 128.55, 128.50, 125.41,
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125.35. ESI MS calcd for C38H26N8Ru [M]+696.13, [M]2+ 348.1 found [M]+841.1 (PF6),
[M]2+ 348.0. Purity by HPLC: 98.7% by area. UV/Vis (MeCN) ε: 255 nm (40600), 285
(85000), 367 (16400), 448 (16000).
Ru(bpy)2dmppz, GL010:
Yield: 133 mg (35%). 1H NMR (CD3CN, 400 MHz):  9.78 (d, J = 8.2 Hz, 2H), 8.53 (d, J
= 8.0 Hz, 2H), 8.47 (d, J = 8.2 Hz, 2H), 8.41‐8.39 (m, 2H), 8.09‐7.99 (m, 4H), 7.86 (d, J
= 5.1 Hz, 2H), 7.79‐7.72 (m, 4H), 7.34‐7.28 (m, 4H), 2.16, (s, 6H). 13C NMR (CD3CN): 
169.73, 158.67, 158.50, 154.12, 152.99, 152.67, 143.97, 140.32, 139.08, 138.89,
135.25, 133.23, 130.57, 129.63, 129.50, 128.60, 128.50, 125.66, 125.55, 26.48. ESI
MS calcd for C40H30N8Ru [M]+724.16, [M]2+ 362.1 found [M]+723.3, [M]2+362.1.Purity
by HPLC: 97.4% by area. UV/Vis (MeCN) ε: 284 nm (88900), 325 (23600), 352
(18900), 450 (14100).
Ru(bpy)2biq, GL011:
Yield: 772.4 mg (99%). 1H NMR (CD3CN, 400 MHz): 8.96 (d, J = 8.8 Hz, 2H), 8.78 (dd,
J = 8.4, 1.1 Hz, 2H), 8.72 (d, J = 8.8 Hz, 2H), 8.65 (dd, J = 8.2, 1.1 Hz, 2H), 8.39 (dd, J =
5.3, 1.1 Hz, 2H), 8.29 (q, J = 8.9 Hz, 4H), 8.01‐7.98 (m, 4H), 7.91 (d, J = 5.3 Hz, 1H),
7.89 (d, J = 5.3 Hz, 1H), 7.64 (d, J = 5.5 Hz, 2H), 7.62 (d, J = 5.5 Hz, 1H), 7.47 (td, J =
7.9, 0.9 Hz, 2H), 7.11 (d, J = 8.8 Hz, 2H), 7.05‐7.01 (m, 2H).

13C

NMR (CD3CN): 

161.95, 1588.69, 154.08, 152.15, 149.24, 148.54, 140.36, 138.49, 138.29, 132.36,
132.14, 132.00, 130.57, 130.10, 1129.98, 129.27, 129.14, 127.22, 126.89, 125.73,
122.08. ESI MS calcd for C42H28N6Ru [M]+718.14, [M]2+ 359.1, found [M]+718.3, [M]‐
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2+359.

Purity by HPLC: 99.9 % by area.UV/Vis (MeCN) ε: 218 nm (78000), 338

(28400), 378 (19300), 440 (8300), 525 (8300).
Ru(bpy)2‐2,2’‐biq‐4,4’‐dca, GL013
ESI MS calcd for C40H28N6O4Ru [M]+758.12, [M]2+ 379.1 found [M]+757.3, [M]2+379.0.
Ru(bpy)2bathocuprione, GL014
Yield: 607.8 mg (98.2 %). 1H NMR (CD3CN, 400 MHz): 8.61 (d, J = 8.0 Hz, 2H), 8.54
(d, J = 8.2 Hz, 2H), 8.10 (td, J = 7.9, 1.1 Hz, 2H), 8.04‐7.98 (m, 4H), 7.88 (d, J = 5.5 Hz,
2H), 7.82 (d, J = 5.3 Hz, 2H), 7.61‐7.52 (m, 12H), 7.42 (t, J = 7.0 Hz, 2H), 7.34 (t, J = 6.9
Hz, 2H), 2.01 (s, 6H).

13C

NMR (CD3CN): 167.48, 158.73, 158.47, 153.96, 152.86,

150.51, 150.33, 138.89, 138.72, 136.85, 130.77, 130.62, 130.12, 128.88, 128.51,
128.43, 128.35, 125.86, 125.56, 125.47, 26.47.16ESI MS calcd for C46H36N6Ru [M]‐
+774.2,

[M]2+ 387.1,found [M]+773.3, [M]2+387.1.Purity by HPLC: 95.0% by

area.UV/Vis (MeCN) ε:290 (74100), 454 (15600).
Ru(dmphen)2‐8HQ, GL018:
Yield:55 mg (24%). 1H NMR (CD3CN, 400 MHz): 8.51‐8.44 (m, 2H), 8.30 (d, J = 8.4
Hz, 1H), 8.19‐7.97 (m, 5H), 7.81‐7.74 (m, 1H), 7.69 (d, J = 8.2 Hz, 1H), 7.61 (J = 8.2
Hz), 7.35 (dd, J = 8.4, 2.9 Hz, 2H), 7.09 (t, J = 8.0 Hz, 1H), 6.72‐6.64 (m, 3H), 6.25 (d, J
= 8.0 Hz, 1H).

13C

NMR (CD3CN):  169.81, 169.31, 169.00, 168.78, 167.87, 167.53,

167.43, 166.80, 160.28, 160.27, 152.13, 152.05, 151.35, 151.19, 149.95, 149.53,
149.02, 147.06, 136.59, 136.47, 136.43, 135.95, 135.52, 130.49, 130.38, 130.30,
129.99, 127.81, 127.59, 127.52, 127.41, 126.10, 126.07, 26.311, 26.27, 25.04, 24.57.
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ESI MS calcd for C37H30N5ORu [M]+662.15, found [M]+662.1.Purity by HPLC: 99.9%
by area.UV/Vis (dH2O) ε: 224 (64700), 268 (52000), 450 (8100), 497 (8800), 620
(9900).
Ru(dmphen)2‐2Me8HQ, GL019:
Yield: 96 mg (58 %). 1H NMR (CD3CN, 400 MHz):  8.40‐8.36 (m, 3H), 8.29 (d, J = 8.4
Hz, 1H), 8.23 (d, J = 8.2 Hz, 1H), 8.10‐8.02 (m, 5H), 7.88 (s, 1H), 7.75 (d, J = 8.6 Hz,
1H), 7.69‐7.64 (m, 2H), 7.44 (d, J = 8.2 Hz, 1H), 7.38 (d, J = 8.2 Hz, 2H), 7.00 (t, J = 7.8
Hz, 1H), 6.66 (d, J = 8.6 Hz, 1H), 6.60 (d, J = 7.8 Hz, 1H), 6.16 (d, J = 7.8 Hz, 1H), 2.24
(s, 3H). 13C NMR (CD3CN, 400 MHz): 170.51, 168.99, 168.93, 168.76, 166.66, 161.79,
160.31, 160.28, 160.25, 160.25, 160.24, 154.79, 151.79, 151.72, 146.52, 137.94,
136.66, 136.55, 136.21, 135.77, 130.33, 130.21, 129.97, 129.90, 129.85, 129.13,
127.72, 127.7, 127.60, 127.36, 127.20, 127.13, 126.81,26.64, 26.38, 24.67, 24.66,
24.03. ESI MS calcd for C38H32N5ORu [M]+676.17, found [M]+676.1. Purity by HPLC:
97.0% by area. UV/Vis (MeCN) ε: 225 nm (62500), 272 (56400), 500 (8800).
Ru(bpy)2dpq, GL021:
Yield: 237 mg (66 %). 1H NMR (CD3CN, 400 MHz):  9.55 (d, J = 8.2 Hz, 2H), 9.23 (sd,
J = 0.6 Hz, 2H), 8.56 (dd, J = 7.8, 7.8 Hz, 6H), 8.22 (dd, J = 5.3, 0.6 Hz, 2H), 8.14 (t, J =
7.8 Hz, 2H), 8.03 (t, J = 7.6 Hz, 2H), 7.92‐7.87 (m, 4H), 7.68 (d, J = 5.6 Hz, 2H).

13C

NMR (CD3CN):  158.86, 158.61, 155.34, 153.75, 153.70, 153.64, 153.61, 150.89,
147.37, 141.45, 139.60, 139.49, 134.93, 131.83, 129.27, 129.21, 129.11, 129.06,
128.74, 125.96, 125.89.16 ESI MS calcd for C34H324N8Ru [M]+646.12, found [M]+645.9.
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Purity by HPLC: 95.4% by area. UV/Vis (MeCN) ε:256 nm (53600), 289 (55900), 449
(15100).
Ru(dmphen)2bpy, GL022:
Yield: 98 mg (20 %). 1H NMR (CD3CN, 400 MHz): 8.66 (d, J = 8.24 Hz, 2H), 8.33 (d, J
= 8.42 Hz, 2H), 8.25 (d, J = 879 Hz, 2H), 8.18 (d, J = 8.24 Hz, 2H), 8.11 (d, J = 8.42 Hz,
2H), 7.83‐7.75 (m, 4H) 7.41 (d, J = 8.2 Hz, 2H), 7.03 (d, J = 5.86 Hz, 2H), 6.99‐6.95 (m,
2H), 2.16 (s, 12H).

13C

NMR (CD3CN):  169.68, 167.74, 158.96, 153.04, 150.42,

149.39, 138.98, 138.86, 137.82, 131.06, 130.96, 128.51, 128.37, 128.23, 127.96,
127.62, 124.90, 26.85, 25.77. ESI MS calcd for C38H32N6Ru [M]+674.17, [M]2+ 337.1,
found [M]+673.2, [M]2+337.0. Purity by HPLC: 94.0% by area. UV/Vis (MeCN) ε: 270
nm (52100), 290 (29500), 457 (9000).
Ru(dmphen)2bathophen, GL023:
Yield: 101.8 mg (49 %). 1H NMR (CD3CN, 400 MHz):  8.75 (d, J = 8.4 Hz, 2H), 8.30 (d,
J = 8.0 Hz, 4H), 8.15 (d, J = 8.8 Hz, 2H), 7.99 (s, 2H), 8.36 (d, J = 8.4 Hz, 2H), 7.56‐7.55
(m, 6H), 7.46‐7.44 (m, 6H), 7.32‐7.28 (m, 4H), 2.02 (s, 12H).

13C

NMR (CD3CN): 

168.72, 166.96, 152.53, 149.46, 149.19, 148.95, 148.32, 137.96, 136.74, 135.29,
130.19, 129.98, 129.74, 129.72, 129.06, 128.30, 127.43, 127.31, 127.28, 126.59,
125.89, 125.27, 26.14, 24.84. ESI MS calcd for C52H41N6Ru [M]+851.24, found [M]‐
+424.8.

Purity by HPLC: 99.9% by area. UV/Vis (MeCN) ε: 220 nm (82300), 270

(80100), 470 (16700).
Ru(dmphen)2dqp, GL039:
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Yield: 101.8 mg (49 %). 1H NMR (CD3CN, 400 MHz):  8.73 (d, J = 8.4 Hz, 2H), 8.42‐
8.39 (m, 2H), 8.31‐8.24 (m, 5H) 8.12 (d, J = 8.8 Hz, 2H), 8.06‐8.05 (m, 2H), 7.83 (d, J =
8.4 Hz, 2H), 7.38‐7.33 (m, 5H), 7.22 (d, J = 8.2 Hz, 2H), 2.16 (s, 12H).

13C

NMR

(CD3CN):  169.81, 167.92, 154.09, 140.52, 149.37, 149.34, 139.01, 138.20, 137.63,
131.00, 129.01, 128.51, 128.29, 128.23, 127.52, 126.17, 26.88, 25.88.16 ESI MS calcd
for C42H432N8Ru [M]+750.18, [M]2+ 375.1 found [M]+749.8, [M]2+375.0. Purity by
HPLC: 98.1% by area. UV/Vis (MeCN) ε: 224 nm (79900), 268 (79400), 459 (14900).
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Table 2.1: Ligand structures used in complexes with corresponding acronyms
Ligand Structure

Chemical Name

Acronym

2,2’‐bipyridine

bpy

6,6’‐dimethyl‐2,2’‐
bipyridine

1,10‐phenanthroline

dmbpy

phen

2,9‐dimethyl‐1,10’‐
phenanthroline

dmphen

dipyrido[3,2‐f:2’,3’‐h‐
quinoxaline]

dpq

dimethyl‐dipyrido[3,2‐
f:2’,3’‐h‐quinoxaline]
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dmdpq

Table 2.1 cont): Ligand structures used in complexes with corresponding acronyms
Ligand Structure

Chemical Name

Acronym

dipyrido[3,2‐2',3'‐
c]phenazine

dppz

dimethyl‐dipyrido[3,2‐
~:2',3'‐c]phenazine

dmdppz

4,7‐diphenyl‐1,10‐
phenanthroline

bp

2,9‐dimethyl‐4,7‐
diphenyl‐1,10‐

bc

phenanthroline

4,7‐diphenyl‐sulfonate‐
1,10‐phenanthroline
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bpds

Table 2.1 cont): Ligand structures used in complexes with corresponding acronyms
Ligand Structure

Chemical Name

Acronym

2,9‐dimethyl‐4,7‐
diphenyl‐sulfonate‐1,10‐

bcds

phenanthroline

2,2’‐biquinoline

biq

8‐hydroxyquinoline

8HQ

2‐methyl‐8‐
hydroxyquinoline

3,3‐dicarboxylic acid‐2,2‐

2Me8HQ

2,2’‐biq‐3,3’dca

biquinoline

2‐phenyl‐pyridine
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cyclobpy

Table 2.1 cont): Ligand structures used in complexes with corresponding acronyms
Ligand Structure

Chemical Name

Acronym

7,8‐benzoquinoline

cyclophen
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Table 2.2: Complex structures with corresponding code
Complex Structure

Code
GL001

GL002

GL003

GL004

GL005
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Table 2.2 (cont.): Complex structures with corresponding code
Complex Structure

Code

GL006

GL007

GL008

GL009
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Table 2.2 (cont.): Complex structures with corresponding code
Complex Structure

Code

GL010

GL011

GL013

GL014

GL018
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Table 2.2 (cont.): Complex structures with corresponding code
Complex Structure

Code

GL019

GL021

GL022

GL023
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Table 2.2 (cont.): Complex structures with corresponding code
Complex Structure

Code

GL024

GL034

GL035

GL039
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Purity of Synthesized Complexes by HPLC
Chloride salts of the ruthenium complexes were injected on an Agilent 1100 Series
HPLC equipped with a model G1311A quaternary pump, G1315B UV diode array
detector and Chemstation software version B.01.03. Chromatographic conditions
were optimized on a Column Technologies Inc. C18, 120 Å (250 mm x 4.6 mm inner
diameter, 5 μm) fitted with a Phenomenex C18 (4 mm x 3 mm) guard column. The
detection wavelength was 280 nm. Mobile phases used were 0.1% formic acid in
dH2O and 0.1% formic acid in HPLC grade acetonitrile. See table below for gradient
used.
Table 2.3: HPLC gradient used to test purity of synthesized ruthenium complexes
Time (minutes)

0.1% formic in dH2O

0.1 % formic in MeCN

0

98

2

2

95

5

5

70

30

15

70

30

20

40

60

30

5

95

35

98

2

40

98

2
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Chapter 3. Photochemisty of Ruthenium Complexes: Characterization by UV‐
Vis Spectroscopy and Mass Spectrometry
1. Introduction
Successful PDT complexes should efficiently produce the desired active
species upon light activation, but not react so quickly under ambient light conditions
as to inhibit administration of the drug. Moderate light stability is required to
ensure that the product can be efficiently handled and transferred by medical
personnel to the patient, and upon light activation, provide the desired cytotoxic
product. However, the complexes have to react sufficiently quickly for the patient to
get an appropriate light dose in a short time to be medically useful. Photoejection
experiments of the complexes were monitored by UV‐Vis to observe the rate of
conversion of ruthenium complex reactants to products. Mass spectrometry was
used to characterize the photochemical products of the reactions. This provides the
identity of the active species that is responsible for the biological effects observed in
Chapters 4 and 5.
Ruthenium complexes that are not sterically strained do not exhibit photo‐
degradation due to the low efficiency of population of the 3MC excited state after
photoexcitation at room or physiological temperatures (22 or 37 ˚C).

These

compounds are stable in the presence of light. Several unstrained complexes were
synthesized to act as control compounds. Alternatively, several strained complexes
have been synthesized that are capable of populating the 3MC state, resulting in
ligand ejection upon light activation (see Chapter 2.2).
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2 Photoejection Experiments Monitored by UV‐Vis Spectroscopy
UV‐Vis spectroscopy was used to observe the absorbance properties of the
synthesized ruthenium complexes. Due to the number of complexes analyzed for
this study, all absorption profile figures are included at the end of the chapter.
Figure 3.1 shows the typical absorbance spectra of ruthenium complexes that
are stable in the presence of light. Complexes GL004, 009, and 021 display an
absorbance maximum at ~450 nm, and the absorption spectra do not change upon
exposure to light.
In contrast, sterically hindered, octahedral ruthenium complexes can
successfully shuttle electrons into the 3MC excited state with blue light activation
(see Figure 2.2). Exposure to blue light was punctuated by periodic UV‐Vis scans in
order to track the conversion of the starting complex to the photoproduct. The
difference in absorbance at ~495 nm vs ~410 nm (A495‐410) were plotted against
time (minutes) to show the time dependence for the photochemical reactions.
Curves were fit and kinetic half‐lives were determined with a ‘one phase association’
equation to yield the calculated half‐life (t1/2) of the complex using Prism software.
Spectral changes observed for photo‐ejecting complexes are displayed in Figure 3.2
and t1/2 values are summarized in Table 3.1.
GL002 displays a good balance of light activated activity, with a near‐optimal
half‐life of 1.9 minutes observed for the complex. The complex employs the
Ru(bpy)2 backbone and ejects the strained 6,6’‐dimethyl‐2,2’‐bipyridine ligand (see
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Table 3.2). Structural differences in the sterically strained ligand produce different
ejection profiles. For example, GL007 has a half‐life of 112.8 minutes, ~60 times
slower than GL002 (see Table 3.1). GL007 does not incorporate the 6,6’‐dimethyl‐
2,2’‐bipyridine ligand; instead, it contains 2,9‐dimethyl‐1,10‐phenanthroline (see
Table 2.1). An apparent trend is that complexes utilizing the 6,6’‐dimethyl‐2,2’‐
bipyridine ligand tend to degrade faster than fused ring systems such as 1,10‐
phenanthroline. Increasing the planar surface in the fused ligands by adding a
dmdpq (complex GL003) or dmdppz (complex GL010) ligand (see Table 2.1) to the
Ru(bpy)2 scaffold further supports this observation. GL003 has a long half‐life of
60.9 minutes, and GL010 has a half‐life greater than 6 hours. In order to obtain an
ejection profile for GL010, intense white light was employed instead of blue light
used in other studies. Under these conditions, the half‐life of the complex is 20.5
minutes (see Table 3.1).
The differences in photoreaction half‐lives provide useful guidelines for the
development of these complexes, and it is clear that strained bipyridine ligands eject
faster than fused ring systems incorporated in complexes such as GL003, 007, 010
(see Table 3.3). Recoordination of more rigid ligands such as dmphen, dmdpq, and
dmdppz (see Table 2.1) appears to occur readily, hindering the complete photo‐
dissociation of the ligand and resulting in longer half lives (see Table 3.1). The
enhanced photoejection rate for complexes of 6,6’‐dimethyl‐2,2’‐bipyridine is
thought to be due to the ability of the ligand to rotate freely around the C2‐C2’ bond,
thwarting recoordination and resulting in ligand loss.
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The half‐lives of the ruthenium complexes are summarized in Table 3.1. The
fastest ejecting complexes are the ones utilizing the 2,2’‐6,6’‐dimethyl‐bipyridine
ligand. Complex GL002 and 005 have half‐lives of 1.9 and 0.6 minutes respectively.
Moving the methyl group around the bipyridine ligand to the 3,3’ positions provides
a different type of steric clash (“backside clash”) seen in complex GL006,
significantly increasing the t1/2 to 230 minutes.
The ejection kinetics for GL002 are ~50 fold faster than GL011, a complex
containing a biquinoline ligand. It was thought that the addition of a phenyl ring to
the 2,2‐bipyridine motif to make the biquinoline ligand would provide more steric
clash and thus a faster photoactive complex. This was not observed, and is thought
that the size of the six methyl hydrogens provides more steric clash compared to the
bulk of the biquinoline ligand with two benzyl hydrogens.
To observe the effect of electron withdrawing groups on ejection kinetics,
GL008 and 014 were synthesized. Both compounds contain the same Ru(bpy)2
backbone and only differ by the addition of sulfonate groups to complex GL008 (see
Table 2.2). A six‐fold increase in the ejection kinetics was observed for GL008 and
014, with t1/2 values of 12.6 and 59.7 minutes respectively (see Table 3.1). The
addition of these groups may have a negative effect on the ability of the nitrogen
atoms to efficiently donate their electrons to the ruthenium center and could be
another mechanism by which the ejection kinetics can be tuned.
However, addition of electron withdrawing carboxylic acid groups to the
biquinoline ligand appear to have the opposite effect when comparing complexes
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GL011 and 013 (see Table 2.2). Complex GL013, contains carboxylic acid groups at
the 4,4’ positions and displays the slowest ejection kinetics observed under blue
light, with a t1/2 of greater than six hours (see Table 3.1). Intense white light was
also used on this complex to get an ejection profile in a timely manner. Under
intense white light, the observed t1/2 was 242.3 minutes. Reduction of the electron
donating ability of the nitrogen atoms through the addition of electron withdrawing
carboxylic groups is not observed in complex GL013. Additional complexes with the
same bis‐1,10‐phenanthroline backbone containing ligands such as 6,6’‐dimethyl‐
2,2’‐bipyridine with carboxylic acid groups at the 4,4’ position should be
synthesized to understand why complex GL011 has faster ejection kinetics than
GL013.
The addition of 4,7‐diphenyl groups to the 1,10‐phenanthroline ligand also
appears to hinder dissociation. A three fold kinetic difference (5.4 and 15.2 minutes
respectively) is observed in the half‐lives of GL022 and 023. It is possible that the
addition of the para‐electron donating phenyl groups stabilize the nitrogen‐
ruthenium bond, hindering photo‐dissociation. The 6,6‐dimethyl‐4,7‐diphenyl‐2,2’‐
bipyridine analogue containing complexes that contain the electron donating phenyl
groups at the meta and ortho positions could be synthesized to observe how the
position of the electron withdrawing groups affects the kinetic activity.
Complexes containing different backbones have also been prepared. GL018,
019, 022, and 023 contain the Ru(dmphen)2 backbone, and have different ejection
profiles. The quinoline containing compounds GL018 and 019 display different
46

kinetics, even though the only difference between the complexes is the addition of a
methyl group at the two‐position on the quinoline ligand. Modeling may be
necessary to understand why GL018 ejects faster, and produces a mix of products
(see Table 3.2) as opposed to the more sterically hindered GL019, which ejects
slower and produces one photo‐dissociation product.
Very reactive complexes containing two sterically hindered ligands such as
the Ru(dmbpy)2 starting material with 2,2’‐bipyridine as well as the slower ejecting
dmdpq ligand were synthesized. Products of these reactions were confirmed by the
absence of an emissive spot on thin layer chromatography and by mass
spectrometry of the reaction mixture, but the compounds readily degraded upon
flash chromatography purification and were unable to be characterized. This
showed that the Ru(dmbpy)2 backbone is too reactive for the generation of useful
complexes for PDT applications.
In order to tune the absorption profiles of the metal complexes, a synthetic
approach was attempted to generate complexes that absorb closer to the infrared
region of the spectrum. Compounds that readily degrade to their corresponding
activated species utilizing longer wavelength light are desirable as the longer
wavelength light is capable of penetrating deeper tissues. The Ru(phen)2Cl2 scaffold
coupled with the biquinoline ligand provides an example of the red shift sought
(GL011, Figure 3.2). The biquinoline ligand was selected for its extended pi system,
as it should reduce the MLCT band energy (see Figure 2.2). As expected, a red shift
in absorbance maxima from the typical 450 nm to 510 nm is observed in complex
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GL011. The strain from the additional ring on the biquinoline ligand produces a
photoejecting complex (see Table 3.2).
The desired red shift was also observed utilizing the cyclometallated ligands
2‐phenylpyridine and 7,8‐benzoquinoline coupled with the Ru(bpy)2 backbone
shown in complexes GL034 and 035 (Figure 3.1) Cyclometallated systems GL034
and 035 are significantly red shifted, as expected, with observed absorbance
maxima centered at 550 nm. However, these compounds do not eject as they are
unstrained and are unable to populate the 3MC excited state. As a result, no spectral
change is observed upon exposure to light. Synthesis of cyclometallated complexes
with the strained Ru(dmphen)2 backbone should be performed to obtain the desired
red shift while producing a photo‐active species capable of photo‐binding DNA.
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Figure 3.1: Non‐photoejecting Complexes
GL004

GL009

GL024
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Figure 3.1: Non‐photoejecting Complexes (cont.)
GL034

GL035
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Figure 3.2: Photo‐ejecting Complexes
GL002

GL003

GL005

GL006
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Figure 3.2: Photo‐ejecting Complexes (cont.)
GL007

GL008

GL010 – white light curve shown

GL011
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Figure 3.2: Photo‐ejecting Complexes (cont.)
GL013

GL014

GL018

GL019
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Figure 3.2: Photo‐ejecting Complexes (cont.)
GL022

GL023

GL039
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Table 3.1: Complex t1/2 values
Complex Code

Complex

t1/2 (minutes)

GL002

Ru(bpy)2dmbpy

1.9

GL003

Ru(bpy)2dmdpq

60.9

GL005

Ru(bpds)2dmbpy

0.6

GL006

Ru(bpy)2-3,3’dmbpy

230

GL007

Ru(bpy)2dmphen

GL008

Ru(bpy)2bcds

GL010

Ru(bpy)2dmdppz

GL011

Ru(phen)2biq

GL013

Ru(bpy)2-2,2’biq-4,4’-dca

GL014

Ru(bpy)2bc

59.7

GL018

Ru(dmphen)2-8HQ

17.3

GL019

Ru(dmphen)2-8H-2MeQ

32.7

GL022

Ru(dmphen)2bpy

5.4

GL023

Ru(dmphen)2bp

15.2

GL039

Ru(dmphen)2dpq

112.8
12.6
>6hrs/20.5*
89.2
>8hrs/242.3*

3.2

*white light used
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2 Active Species Determined by ESI‐Mass Spectrometry
Mass spec experiments were carried out to determine the identity of the
ejected ligand and active ruthenium species produced when the Ru(II) complexes
were light activated. Strained octahedral complexes with accessible 3MC states (see
Figure 2.2) were analyzed at micromolar concentrations to mimic conditions used
for in vitro and in vivo experiments (see Chapters 4 and 5). The expected masses of
the pure complexes were observed pre‐exposure, and the light‐activated ruthenium
species and ejected ligand masses were observed post‐exposure. As some ligands
are observed better than others on the instrument, only qualitative observations
were made about the percent abundance of the ejected ligands. For quantitative
measurements of reaction kinetics, see Table 3.1.
Infusion of the model complex GL002 in the absence of light gives the
expected masses of the complex (M+ = 743 and M2+ = 299). Following white light
activation, infusion of the same sample gives the expected, ejected ligand 6,6’‐
dimethyl‐2,2’‐bipyridine (m/z = 185.0 amu) as well as the activated Ru(bpy)2 (m/z
= 414) species capable of cross‐linking DNA. The half‐life of GL002 is 1.9 minutes
(see Table 3.1) and complete conversion of reactant to product is qualitatively
observed.
Complexes with the same Ru(bpy)2 scaffold such as GL003, 006, 007, 010,
and 014 exhibit similar ejection profiles, producing the more sterically hindered
ligand and giving a single activated Ru(bpy)2 species. Complexes such as GL003,
007, 010, and 014 that contain rigid, fused ring ligands eject more slowly (see Table
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2.1), resulting in incomplete product conversion with two minutes of white light
photo‐activation.
Utilizing the more rigid bis‐1,10‐phenathroline (m/z = 462) backbone
similarly yields the ejection of the single biquinoline ligand (m/z = 257) observed in
complex GL011. Addition of methyl groups to this more rigid backbone such as the
Ru(bis‐2,9‐dimethyl‐1,10‐phenanthroline)2 scaffold displayed in complexes GL018,
019, 022, 023, and 039, produce different active species. GL018 and 022 give a
mixture of activated products when exposed to light. Complex GL018 ejects the 2,9‐
dimethyl‐1,10‐phenanthroline (m/z = 209) and 8‐hydroxyquinoline (m/z = 146)
ligands. Similarly, complex GL021 ejects 2,9‐dimethyl‐1,10‐phenanthroline (m/z =
209) as well as 2,2’‐bipyridine (m/z = 157). How this mixture of activated products
affects the cellular potency is examined in Chapter 5.1. Complexes GL023 and 039
produce similar active species through the ejection of the dmphen ligand.
Complexes GL019 differs from GL018 only by the addition of a methyl group
at the two‐position on the 8‐hydroxyquinoline ligand (see Table 2.1). While GL018
ejects a mixture of products, GL019 only ejects the quinoline ligand (m/z = 160).
These complexes have similar in vitro IC50 results (31 μM, see Table 4.1) forming
cross‐links to DNA. In addition to cross‐links, GL019 also produces single strand
breaks. Both complexes show potential as traditional chemotherapeutics (not light
activated) and are potent on A549 cells, showing nanomolar IC50’s (see Table 5.5).
For a complete discussion on the activities of the quinoline complexes, see Chapter
5.1 A549 Growth Inhibition Assays.
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The ejection properties of complexes with different overall charge states
such as GL005 and 008 (overall charge = 2‐ and 0 respectively) were also examined
(see Table 2.2). Complex GL005 was found to eject the 6,6’‐dimethyl‐2,2’‐bipyridine
ligand (m/z = 185), while complex 008 ejected a 2,2’‐bipyridine ligand (m/z = 157).
A summary of the complexes and the ligands ejected with a qualitative estimate of
the percent conversion to the photo‐activated complex with two minutes of white
light are displayed in Table 3.2.
Table 3.2: Ejection products observed by ESI‐MS
Estimated
Percent
Abundance of
Ejected Ligand
100
60
100
60
40
50

Ruthenium
Complex
Code

Name

Ejected ligand

GL002
GL003
GL005
GL006
GL007
GL008

Ru(bpy)2dmbpy
Ru(bpy)2dmdpq
Ru(bpds)2dmbpy
Ru(bpy)2‐3,3’dmbpy
Ru(bpy)2dmphen
Ru(bpy)2bcds

dmbpy
dmdpq
dmbpy
3,3’dmbpy
dmphen
bcds

GL010
GL011
GL013

Ru(bpy)2dmdppz
Ru(phen)2biq
Ru(bpy)22,2’biq‐3,3’dca

90
50
10

GL014
GL018
GL019
GL022
GL023

Ru(bpy)2bc
Ru(dmphen)28HQ
Ru(dmphen)2‐2‐Me‐8HQ
Ru(dmphen)2bpy
Ru(dmphen)2bp

dmdppq
biq
2,2’biq‐
3,3’dca
bc
8HQ/dmphen
2MeHQ
bpy/dmphen
dmphen

GL039

Ru(dmphen)2dpq

dmphen

80
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40
60
50
80
50

3. Reaction of GL002 with Mixed Nucleosides by ESI‐MS
Cisplatin is known to preferentially react with the N7 position of guanosine
(see Figure 1.1).1 To a lesser extent, the complex also has an affinity for the N1 and
N7 positions of adenosine as well as the N3 position of cytidine.2 Cisplatin has
limited to no reactivity with thymidine.3 To determine which bases GL002 reacts
with, a 2:1 ratio of GL002: individual nucleosides (guanosine, adenosine, cytidine, or
thymidine) were studied via ESI‐MS. Dark control experiments were ran parallel
with light activated samples and incubated for one hour before MS analysis. All dark
control samples displayed similar results. Masses of GL002 (M+ m/z = 597, M2+ m/z
= 298) were observed in all samples with the individual nucleoside masses
(adenosine m/z = 268, thymidine m/z = 242, cytidine m/z = 242, guanosine m/z =
284). Infusion of light activated reactions yielded complexes with all of the bases,
though to a much lesser extent with thymidine. The masses observed for photo‐
activated GL002 are the active species, Ru(bpy)2 (m/z = 414) and the ejected ligand
dmbpy (m/z = 185). Reactions with adenosine and photo‐activated GL002 rendered
a complex masses of m/z = 680 (expected m/z = 681), which corresponds to the
Ru(bpy)2 (m/z = 414) active species plus adenosine (m/z = 268). The GL002‐
thymidine complex was found at very low abundance (m/z = 655, expected m/z =
656). Reactions with GL002‐cytidine yielded a complex mass of m/z = 656
(expected 657). Guanosine produced the most abundant signal with M+1 m/z = 696
(expected 697). This was expected due to cisplatin’s preference to the base.1
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4. Reaction of GL002 with Mixed Nucleosides by LC‐MS
To determine the nucleoside preference of GL002, the complex was activated
and added to a mixture of the individual bases (A, C, T, G combined in equal parts),
and analyzed on the LC‐ESI mass spectrophotometer. 1200 μM GL002 was added to
the nucleoside mixture (at 40 μM per base) following photoejection (1:1 complex:
individual base) and injected. A mixed nucleoside‐only sample was prepared at 40
μM per base and injected to serve as a standard and to calculate the percent
recovery of the individual bases (see Figure 3.3). Retention times observed of the
injected bases are: Cytidine, 13.8 minutes; Adenosine, 19 minutes; Guanosine, 19.8
minutes; Thymidine, 22.1 minutes (the slight shift in retention times of the bases
observed upon the addition of GL002 in Figure 3.3b is due to inefficient
equilibration of the column prior to injection. The method should be extended to 60
minutes, returning the gradient to 5% B at 55 minutes to allow adequate column
requilibration prior to subsequent injections. Complex masses similar to those
found above were observed with all nucleosides in low abundance. Addition of the
peak at RT = 22.8 minutes contains the mass of the active species Ru(bpy)2 plus
guanosine (m/z = 696) is displayed in Figure 3.3c. Percent recovery was calculated
using the Varian MS Workstation software. Preference to guanosine is observed
through an 8% loss of guanosine in the base: complex sample when compared to the
standard.
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Figure 3.3: a) 40 μM mixed nucleosides (peaks in order: C, A, G, T); b) 1:1 GL002
with mixed nucleosides (C, A, G, 002 plus G, T; c) GL002: guanosine observed masses
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5. Light Titration of GL002 monitored by ESI‐MS
In order to determine the reactivity of GL002 with light by ESI‐MS, a photoactivation
experiment was performed while flowing sample into the spectrometer. This light
titration experiment was carried out using the aforementioned ESI‐MS setup with
the addition of a flashlight to provide a light source to photo‐activate the ruthenium
complex. Dual ion monitoring mode was utilized to observe the dissociation of the
complex. The m/z = 299 ion corresponds to the unactivated M2+ complex. The m/z =
185 ion corresponds to the ejected 6,6’‐dimethyl‐2,2’‐bipyridine ligand. The
isosbestic point observed at ~1.5 minutes parallels the half‐life observed in Table
3.1. This mass screening analytical technique provides both the kinetics and the
identity of the active species produced by the ruthenium complexes.
Figure 3.4: Light titration of GL002
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6. Experimental
Absorbance measurements were obtained using an Agilent 8353 UV‐Vis
Spectrophotometer equipped with Agilent Chemstation Version B.02.01 sp1
software using a 1 cm cuvette. The instrument was blanked on the solvent used in
the specific experiment. Compound concentrations were ca. 30 μM, and the initial
dark control was scanned followed by exposure to blue light with Dell 1410X
projector/200 W light source. Samples were placed 12 inches from the light source.
Scans were taken periodically at set times to monitor the development of the
degradation species and active species products until no change in the spectra was
observed. Kinetics were calculated using Prism software to give photochemical half‐
lives.
Mass spectrometry experiments were carried out on a Varian 1200L
Quadrupole MS/MS ESI mass spectrometer equipped with Varian MS Workstation
Version 6.42 and Harvard Apparatus Pump 11 syringe pump. ~1 mg/mL complexes
were prepared (chloride salts in water/PF6 salts in acetonitrile) and kept from light.
Micromolar

solutions

of

each

complex

were

infused

in

80:20:0.1%

methanol:water:formic acid before and after two minute light exposure with a 410
W light source (see Ch. 5 In vivo experimental) to observe the initial and light
activated complex masses.
Reactions with nucleosides:
Guanosine (cas 118‐00‐3) was obtained from Alfa Aesar. Adenosine (cas 58‐
61‐7) and cytidine (cas 65‐46‐3) were obtained from Sigma. Thymidine (cas 50‐89‐
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5) was obtained from TCI. All reagents were used without further purification. Stock
DMSO solutions of the individual nucleosides were prepared. Mixtures of the
individual bases with GL002 were prepared at 1:2 (150 μM nucleoside: 300 μM
GL002) ratios. Dark control samples were prepared through the addition of the
nucleoside with GL002 and protected from light wrapped in aluminum foil. Light
activated samples were prepared through the addition of the nucleoside with GL002
and placed under the aforementioned Dell projector for 1 hour. Samples were
infused in 80:20:0.1% methanol:water:formic acid on the previously mentioned ESI
mass spectrophotometer. Dark control samples were infused under low light room
conditions with the syringe wrapped in aluminum foil.
Nucleosides used are described above. 1:1 GL002 (1200 μM): nucleoside
(300 μM each) concentrations were used to obtain the results. Using stock DMSO
solutions of the nucleosides, a mixture was prepared at 300 μM per base and was
added to photo‐ejected GL002 in dH2O and allowed to incubate at 37 oC for 2 hours.
A nucleoside only sample was prepared at identical concentration of 300 μM per
base in dH2O to serve as a standard and to calculate percent recovery. A blank
solution was prepared to mimic DMSO concentrations in dH2O. The experiment was
carried out with the previously mentioned ESI mass spectrophotometer with the
addition of the two Varian ProStar pump (model 210). 10 μL were injected on a C18
column (Column Technologies Inc., 5μm 120 A, 4.5x25 cm, part number
CTI0DS546250) at 0.25 mLmin‐1 using the following gradient:
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Table 3.3: HPLC gradient used for GL002:mixed nucleoside HPLC‐Ms experiment
Time
0.1 % Formic Acid/miliQ‐H2O

0.1 % Formic Acid/MeCN

0

95

5

2

95

5

18

70

30

22

70

30

35

5

95

38

5

95

39

95

5

53

100

0

55

100

0

(minutes)

Light Titration of GL002:
Micromolar

solutions

of

GL002

were

infused

in

80:20:0.1%

MeOH:dH2O:Formic Acid and acquired on the previously mentioned ESI mass
spectrophotometer. Sample was infused in the dark and was exposed to light with a
standard Rayovac IN2 flashlight. The photo‐ejection of GL002 was observed
following m/z ions 299 (M2+) and the dissociated ligand dmbpy (m/z = 185). Curves
were generated using Prism software using the ‘one phase association’ equation.
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Chapter 4: In Vitro Studies of Light‐Activated Ruthenium Complexes
Other scientists including Dr. David Heidary and Erin Wachter contributed to this
this chapter.
Introduction
The goal of this project is to synthesize photoactive complexes that form
cross‐links with DNA, leading to cell death. A distinction between dark and light
activated DNA damage is required for successful photodynamic therapy. Dark
toxicity should be minimized in order to avoid unnecessary damage to the healthy
tissue surrounding the area to be treated. In order to test these effects, in vitro DNA
damage studies were performed using the pUC19 plasmid DNA.
4.1. DNA Damage Studies by Gel Electrophoresis
In vitro gel electrophoresis experiments were carried out with pUC19
plasmid DNA to analyze the DNA damage caused by the synthesized ruthenium
complexes either in the dark or through light activation. The activity of the
complexes was compared to the chemotherapeutic cisplatin, the prototypical
inorganic DNA damaging agent. Cisplatin cross‐links DNA, which results in the
induction of cell death, but a significant drawback is that it does not distinguish
between healthy and cancerous cells.1 Unwinding of platinated pUC19 DNA is
observed through the decreased mobility of the DNA in the agarose gel with
increasing cisplatin concentrations (see Figure 4.1). The decreased mobility of the
DNA is a result of increasing platination of the DNA with increasing concentrations
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of cisplatin. An IC50 value of cisplatin was determined based on the concentration of
the compound that resulted in the pUC19 plasmid existing in a state where it was
unwound by 50%. This was observed at 31 μM with the complete unwinding
occurring at 100 μM.
Figure 4.1: Cisplatin with pUC19 DNA

To determine the type of DNA interaction or damage that could occur with
the ruthenium complexes, DNA damage was induced with other control compounds
and agents. The metal complex copper phenanthroline (Cu(phen)2) is known to
produce single strand breaks by nicking the DNA forming the relaxed circular
plasmid DNA.2 This complex serves as a standard for single strand breaks to the
pUC19 DNA and is included on all gels. Alternatively, complexes that form double
strand breaks are highly desirable. This effect is included as a standard on gels
through the use of the restriction enzyme EcoRI.3 Severe damage to the DNA
through double strand breaks produces linear DNA leading to cell death. Double
strand breaks require homologous recombination or nonhomologous end‐joining
repair mechanisms. This type of damage is most severe because neither strand can
serve as a template for repair, resulting in cell death upon the subsequent cell cycle.4
Complexes that display this ability should be addressed in future work.
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40 μg/mL pUC19 DNA was dosed with increasing amounts of each ruthenium
complex followed by irradiation with blue light for one or three hours. Initial
samples were pulled before light activation, and were protected from light to serve
as the dark control. Due to the numerous compounds synthesized, this chapter will
be divided into the following parts: 1) by active species a) (Ru(bpy)2 and b)
Ru(dmphen)2, 2) complexes that intercalate, and 3) complexes that produce single
strand DNA breaks. A comprehensive table is provided at the end of the chapter that
summarizes the type of damage and IC50’s observed at three hours (Table 4.1). The
digital images of agarose gels for the dark control, one and three hour time points
are included in Figure 4.6. This figure contains all gels produced by complexes in
this thesis. These gels provide information on the types of DNA damage the
complexes create and the concentration of the compound required to achieve the
effect. Combining this mechanistic information with the cell viability can provide
insight into the in vivo results shown in the A549 cell viability assays (see Chapter
5.1).
1a) Complexes that form the Ru(bpy)2 backbone upon light activation
Complexes producing similar active species (for example, Ru(bpy)2, see Table
3.2, ESI‐MS Data) are highlighted in Figure 4.2. Complexes GL002, 003, 006, 007, and
014 produce the same Ru(bpy)2 active species and display cross‐linking ability with
pUC19 DNA with IC50 values of 15, 30, 30, 30, and 15 μM, respectively on the three
hour gel.
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Figure 4.2: Complexes with Ru(bpy)2 active species
GL002

GL003

GL006

GL007

GL014
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The one and three hour gels for GL002 are similar due to the kinetic ability of
the complex to readily produce the active species (t1/2 = 1.9 minutes, see Table 3.1),
which is capable of photo‐binding DNA. GL003, 006, and 007 show similar effects,
but with less potency to the pUC19 DNA with IC50 values of 30 μM. Since the same
species are generated, it is surprising that the IC50 values are not equivalent. This
disconnect is explained by the fact that GL003, 006, 007, and 014 are kinetically
slower to produce the active species with t1/2 values of 62, > 232, 128, and 60
minutes respectively (see Table 3.1). This decreased efficiency to produce the active
species results in the differences observed in the one and three hour time points
associated with the complexes’ gels. The slow ejection is correlated with the more
planar ligands used in the complex (see Table 2.2). The slight smearing of GL003 at
the 3 hours time point is indicative of the intercalating ability of the dmdpq ligand
into the base stack of the DNA and the subsequent unwinding of the DNA.5
Smearing due to intercalation is also observed in its’ non‐photoejecting analogue,
GL021. This complex is an efficient single strand DNA breaker and has an IC50 of 30
μM. The gels for GL003 and 007 display both cross‐linking and single strand breaks
at three hours with the pUC19 DNA. It displays the anticipated single strand breaks
associated with other ruthenium‐phenanthroline complexes. This is attributed to
the generation of reactive oxygen species (ROS, see section 3, complexes that
produce single strand DNA breaks with pUC19 DNA). Complex GL014 also shows
similar cross‐linking to GL002 in addition to single strand breaks observed in the
three hour gel. The ability to bind DNA and produce single strand breaks with the
addition of the bathophen ligand might account for the increased dark A549 cell
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viability that is observed (dark IC50 value = 9.3 μM, see Table 5.5). Complexes
containing the bis‐bathophen backbones should be synthesized to increase potency.
The issue with increased dark toxicity could possibly be relegated through the
addition of negatively charged ligands.
1b) Complexes that produce the Ru(dmphen)2 backbone
Other complexes containing similar backbones are highlighted in Figure 4.5.
Complexes GL018, 019, 022, 023, and 039 contain the Ru(dmphen)2 backbone. A
~50 nm red shift in the absorbance is gained through the addition of the dmphen
backbone (see Figure 3.2).
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Figure 4.3: Complexes containing the Ru(dmphen)2 backbone
GL018

GL019

GL022

GL023

GL039

Complexes GL018 and 019 are quinoline‐containing complexes that cross‐
link pUC19 DNA with IC50 values of 30 μM at three hours. GL019 produces single
strand breaks in addition to cross‐links. Quinoline ligands are known to have
cytotoxic capabilities and are discussed in Chapter 2.1.6 Both complexes display in
vitro IC50 values of 30 μM and considerable toxicity to A549 cells with IC50 values of
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0.3 and 0.6 μM respectively (see Table 5.5). Complexes GL022 and 023 are equally
efficient at cross‐linking pUC19 DNA with IC50 values of 15 μM and are considerably
potent on A549 cells with IC50 values of 1.2 μM and 0.2 μM (see Table 5.5)
respectively. The DNA binding/intercalation observed in complex GL023 is thought
to stem from the addition of the bp ligand (see Table 2.2). GL039 efficiently cross‐
links pUC19 DNA as well, with an IC50 value of 15 μM at three hours. In addition to
cross‐links, the complex also produces single strand breaks and intercalates DNA.
The increased DNA affinity stems from the addition of the planar dpq ligand to the
Ru(dmphen)2 backbone and produces similar intercalating results observed in
similar complexes GL003, 009, and 010. The increased DNA affinity is observed in
the A549 cell viability experiment with a dark IC50 result of 49.4 μM (see Table 5.5).
2) Complexes that intercalate pUC19 DNA
Complexes GL009 and 010 were synthesized with the purpose of generating
compounds that strongly interact with the DNA duplex through intercalation. These
compounds contain the dppz ligand (see Table 2.1), which is a large planar system
that allows for intercalation through pi stacking with the bases of DNA. DNA binding
affinity values of 108 M‐1 have been reported in the literature for similar dppz
containing complexes.7 The effects of GL009 and 010 are shown in Figure 4.4.
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Figure 4.4: pUC19 Intercalating ruthenium complexes
GL009

GL010

These compounds display similar results to GL003, where smearing of the
DNA plasmid was observed in the gels. While GL009 shows no cross‐linking because
it is not photoative, GL010 can slowly produce the same Ru(bpy)2 active species
((t1/2 = > 6 hrs), see Table 3.1) resulting in the observed, although slight cross‐
linking at the three hour time point. This is consistent with the narrow in vivo
phototherapeutic window of 2.1 for GL010 (see Table 5.5).
3) Complexes that produce single strand DNA breaks with pUC19 DNA
Ruthenium complexes can generate singlet oxygen, producing single strand
breaks in DNA. This type of damage from the evolution of singlet oxygen is known in
the literature.8 Complexes GL004, 005, 011 and 021 display single strand breaks and
are highlighted in Figure 4.5.
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Figure 4.5: Ruthenium Complexes Producing Single Strand Breaks in pUC19 DNA
GL004

GL005

GL021

GL011

GL004, 011, and 021 have similar planar co‐ligands (phen and dpq) as the
Cu(phen)2 standard and yield similar single strand breaks with IC50 values of 15 and
30 μM respectively. Complex GL005 was synthesized to create an active species that
was negatively charged to assess the importance of charge state in interacting with
the DNA. The IC50 value for complex GL005 is approximately 60 μM at the three
hour time point (note that only about 10% of the pUC19 DNA is converted to single
strand). Producing the active species of GL005 is kinetically, very efficient, with a
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t1/2

of

0.6

minutes

(see

Table

3.1). The

complex

contains

the

bis‐

bathophendisulfonate backbone to give an overall charge of ‐2, while a majority of
the complexes discussed in this work have an overall charge of +2. The yield of
ssDNA produced by GL005 is low compared to GL004. This is thought to be due to
the photoejection, which decreases the yield of 1O2. There is also a decreased
electrostatic interaction with the DNA through the addition of the negatively
charged backbone. This would suggest that GL005 would have very low potency in
cell studies, but a 150‐fold window is observed in the A549 cell viability assay (see
Table 5.5). Limited dark toxicity (200 μM) is also observed in A549 cells supporting
the decreased affinity through the negatively charged backbone. Additional
complexes with similar backbones should be synthesized to prove this hypothesis.
Complex GL011 shows efficient cross‐linking at an IC50 value of 30 μM with
single strand breaks occurring at higher concentrations. The Ru(phen)2 backbone
with the addition of a biquinoline ligand shifts the absorbance to the red by ~60 nm
(see Figure 3.2). A phototherapeutic ratio of 5.4 (see Table 5.5) is observed in the
A549 cell viability assay. Similar derivatives will be important in future research
due to the deeper tissue penetrating nature associated with red shifted
absorbances.9 The IC50’s and type of damage observed at three hours is summarized
in Table 4.1.
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Table 4.1: Summary of IC50 Values and Types of Damage Observed at Three Hours
Complex Code

IC50 (μM)

Type of Damage
Observed

Cisplatin
GL002
GL003

31
15
31

GL004
GL005
GL006
GL007
GL008
GL009
GL010
GL011
GL013
GL014
GL018
GL019
GL021
GL022
GL023

15
31
31
31
62
<7.5
>62
31
No Effect Observed
15
31
31
31
15
15

GL039

15

Cross‐link
Cross‐link/S.S Breaks
Cross‐link/S.S
Breaks/Intercalate
S.S. Breaks
S.S. Breaks
Cross‐link/S.S Breaks
Cross‐link/S.S Breaks
Cross‐link/S.S. Breaks
Intercalate
Intercalate/Cross‐link
Cross‐link/S.S Breaks
No Effect Observed
Cross‐link/S.S Breaks
Cross‐link
Cross‐link/S.S Breaks
Intercalate/S.S. Breaks
Cross‐link/S.S. Breaks
Cross‐link/Intercalate/S.S.
Breaks
Cross‐link/Intercalate/S.S.
Breaks
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Figure 4.6: Ruthenium Complexes with pUC19 DNA
Cisplatin

GL002

GL003

GL004

GL005
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Figure 4.6: Ruthenium Complexes with pUC19 DNA (cont.)
Gl006

GL007

GL008

GL009

GL010

GL011
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Figure 4.6: Ruthenium Complexes with pUC19 DNA (cont.)
GL013

GL014

GL018

GL019

GL021

GL022
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Figure 4.6: Ruthenium Complexes with pUC19 DNA (cont.)
GL023

GL039
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4.2. Reaction of GL002 with Calf Thymus DNA Monitored by UV‐Vis
Spectroscopy
To determine the binding kinetics for the reaction of the activated ruthenium
complex with DNA, 20 μM GL002 was reacted with 100 μM (base pairs) calf thymus
(CT) DNA in 10 mM NaH2PO4 buffer at 37 oC. Control dark reactions with GL002 and
CT DNA yielded very little change in the spectra over 24 hours and are shown in
Figure 4.7a. Figure 4.7b displays the reaction of photo‐activated GL002 upon the
addition of CT DNA, where scans were taken over a period of seven hours to provide
the kinetic profile for the reaction. The CT DNA reacts rapidly, as observed by the
spectral change observed in Figure 4.7b. A decrease in absorbance around 400 nm
with an increase absorbance around 490 nm is observed. To determine the reaction
rate, data was collected in triplicate and the change in absorbance was plotted
against time to create a time course for the reaction. The data was fit to an equation
for a ‘one phase association’ using Prism software and is shown in Figure 4.7c. The
calculated half‐life for the reaction is 52 minutes. The selectivity of GL002 to only
bind the DNA after light‐activation serves as a prodrug model for PDT use.
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Figure 4.7: Kinetic profile of GL002 with 100 μM Calf Thymus DNA: a) Dark reaction,
b) Light activated 002 with CT DNA, c) Light activated kinetics

4.3 Reaction of GL002 with Guanosine Monitored by UV‐Vis spectroscopy
Although cisplatin is capable of binding guanine, cytosine, and adenine, the
preferred base is guanine.10 Cisplatin binds at the N7 position of the base and is
capable of forming interstrand and intrastrand cross‐links.11 Intrastrand cross‐links
between the N7 atoms of adjacent guanine residues produce distortion of the DNA
backbone.1, 12,12a
Once the binding kinetics for the reaction of GL002 with Calf Thymus DNA
were determined (see Figure 4.7) and preference to guanosine was found through
nucleoside selectivity experiments using LC‐MS (see Figure 3.3), the binding kinetics
for GL002 with guanosine was determined using UV‐Vis spectroscopy. This was
assessed by reacting 20 μM GL002 with 1 mM Guanosine in 10 mM NaH2PO4 buffer
at 37 oC. To ensure that the interaction of guanosine was mediated by the activated
GL002, control dark experiments were performed with unactivated GL002. The
results from this control showed that GL002 does not react significantly with
guanosine over several hours. When GL002 was photo‐activated, it reacted quickly
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with guanosine as observed by the spectral change in Figure 4.8b. Data was
collected for two hours following the addition of activated GL002 with guanosine
and the kinetics for the reaction were measured and plotted using the difference in
absorbance at 495 and 410 nm. The curve was fit with ‘one phase association’ with `
Prism software. The calculated half‐life of the reaction is 12.7 minutes.
Figure 4.8: Kinetic Profile of GL002 with 1 mM Guanosine: a) Dark reaction, b) Light
activated 002 with guanosine, c) Light activated kinetics

4.4. Reaction of GL002 with Glutathione Monitored by UV‐Vis Spectroscopy
Glutathione (GSH) is a sulfur containing tripeptide that is highly reactive and
found in most cells. Present in cells at concentrations ranging from 1‐30 mM,13 GSH
plays several roles including antioxidation and maintenance of the redox state. One
of the most important role of GSH is detoxification of carcinogens,13a and elevated
levels of GSH lead to chemotherapeutic drug resistance and aid in cell survival.14
GSH is problematic to cisplatin as the soft thiol groups have a high affinity for the
soft platinum(II) metal. Pearson’s values of hardness (η) for platinum2+ and sulfur
are 8.0 and 4.14, respectively.15 The large difference ensures good covalent overlap
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between the Pt2+ and S atoms. Cisplatin/GSH kinetics are known in the literature
and are relatively fast at a t1/2 = ~53 minutes.13c To determine the binding kinetics
of GL002, 16 mM GSH was reacted with 20 μM GL002 in NaH2PO4 buffer. Addition of
GSH to inactivated GL002 yielded no activity over 48 hours (Figure 4.9a). The ability
to evade detoxification agents like GSH while inactive may allow for effective dosing
of PDT patients with the prodrug GL002. Addition of GSH to photo‐activated GL002
yielded a slow reaction, with a t1/2 = 247.6 minutes. The Pearson’s value of hardness
for Ru2+ is slightly lower than that of Pt2+ at 5.86.15 However, this is an estimate for
the metal only and not for a coordination complex with aromatic ligands, which
affect the electron density of the metal center. This experimental results show that
sulfur has a higher affinity for the platinum in cisplatin over ruthenium in
polypyridyl complexes. This is consistent with some results in the literature that
shows some ruthenium complexes prefer nitrogen to sulfur.16
Figure 4.9: Kinetic Profile of GL002 with GSH: a) Dark reaction, b) Light activated
002 with GSH, c) Light activated kinetics
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Chapter 4: In Vitro Experimental
In Vitro: Agarose Gel Electrophoresis Experimental
Materials:
The pUC19 plasmid DNA was obtained from ATCC and was purified with the
Maxi Prep kit by Qiagen. Buffered solutions containing, tris base, and acetic acid
were obtained from Sigma, VWR or Fisher and were prepared to the appropriate
concentrations using Glazer Lab Agarose Gel Electrophoresis Protocols. Ingredients
for the DNA loading dye include bromophenol blue, xylene cyanol, and glyceron
were obtained from VWR and prepared to appropriate concentrations using Glazer
Laboratory Protocols. Single strand breaks of the plasmid (relaxed circle) were
observed using copper phenanthroline (Cu(phen)2) obtained from Sigma and
prepared via the reaction outlined below. Reagent grade dithiothreitol (DTT) and
H2O2 were obtained from VWR. Double strand (linear DNA) breaks to the pUC19
plasma DNA were observed using the endonuclease enzyme EcoR1 obtained from
Fisher and was prepared per protocol outlined below. A DNA ladder from Promega
was used for mass estimation of DNA fragments produced and was prepared
through the procedure outlined below. Pure agarose was obtained from Fisher and
prepared using the protocol outlined below. Gel rigs used for running the gels were
also obtained from BioRad. Gels were stained with ethidium bromide (Fisher) and
digitally imaged.

86

Single Strand DNA Break Cu(OP)2 Reaction:
Single strand breaks of the pUC19 plasmid DNA were created through the
incubation of 40 μg/mL of pUC19 in 10 mM phosphate buffer, pH 7.4 mixed with 8
μM Cu(phen)2. The reaction was initiated with the addition of 4 μL of 5 mM DTT and
4 μL of 5 mM H2O2. The reaction mixture was vortexed for 10 seconds and allowed
to incubate at room temperature for 30 minutes. Prior to loading onto the agarose
gel, 6 μL of DNA loading dye was added to the sample.
Double Strand DNA break EcoR1 Reaction:
Double strand breaks of the pUC19 plasmid DNA were accomplished through
the incubation of 40 μg/mL of pUC19 with 8 μL of EcoR1, a DNA restriction enzyme,
mixed with 10 μL 10X EcoR1 buffer. The appropriate amount of dH2O was added to
bring the final volume to 100 μL. The solutions were thoroughly mixed and allowed
to react at 37 oC for 90 minutes on a heat block. Upon completion and prior to use,
20 μL of 6X DNA loading dye was added.
DNA Ladder for Mass Estimation of DNA Fragments:
Mass estimation of the DNA fragments produced was observed through the
use of a 1Kbase pair ladder. 10 μL of the 1Kbase pair ladder was diluted 10X with 20
μL of 6X loading dye and dH2O.
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Agarose Gel Preparation:
1% agarose gels were prepared by mixing 0.5 g agarose with 50 mL of 1X tris
acetate buffer and heated to boiling ensure complete dissolution in a microwave.
The solution was then poured into the gel deck with a 15 well comb in place and
allowed to solidify for at least 30 minutes. Once solidified, the gel was placed in the
gel rig filled with 1X tris acetate running buffer.
Sample Preparation: DNA dosing and Light Activation
A dilution series was prepared in clear, 96‐well flat bottom plates (clear,
Costar) of the following ruthenium complex concentrations in 10 mM Na2PO4 buffer:
500 μM, 250 μΜ, 125 μM, 62.5 μM, 31.3 μM, 15.6 μM, 7.8 μM, and 0μM. pUC19
plasmid DNA concentration was added to each well at 40 μg/mL (final volume 90
μL). A 30 μL aliquot was removed for each dose point to serve as the dark control.
The remaining 60 μL were exposed to blue light from a 200 W Dell projector. 30 μL
sample aliquots were removed at 1 hour and 3 hours of light activation. After light
exposure the samples were allowed to react at room temperature overnight. Prior
to loading on the agarose gel 6 μL of 6X DNA loading dye were added to each 30 μL
sample aliquots with 8 μL of the samples being loaded into the gel well. Typical
order of the loaded samples is: DNA ladder, EcoR1, Cu(OP)2, 0 μM ruthenium
complex to 500 μM ruthenium complex, DNA ladder. The gels were run for 75
minutes at 100 mV. Gels were stained with 7.5 μL of ethidium bromide in 150 mL 1X
Tris acetate Buffer for 40 minutes followed by de‐staining of the gels with a fresh
150 mL aliquot of 1X tris acetate buffer for 30 minutes and imaged digitally.
88

4.2 In Vitro: GL002 with Calf Thymus DNA by UV‐Vis spectroscopy: Experimental
Reaction kinetics were obtained for GL002 with Calf Thymus DNA in
NaH2PO4 buffer at pH 7.4 at 37 oC using an Agilent 8353 UV‐Vis spectrophotometer
equipped with Chemstation B.02.01 software and a temperature controller peltier
(Agilent 89090A). Calf thymus DNA was obtained from ATCC and sonicated for 30
minutes to produce uniform breaks in the DNA. The instrument was blanked on 7
μL of 1M NaH2PO4 at pH 7.4 (10 mM) and 691 μL of deionized water in a small
volume cuvette. 2.1 μL of GL002 (6.55 mM) was added to the blank solution to give
002: NaH2PO4 concentrations of 20 μM: 10 mM respectively. Following an initial
scan, the cuvette was placed under the Dell projector (see Chapter 3.1) and exposed
to blue light until no change was observed in the UV spectra confirming the
complete conversion of the complex to the Ru(bpy)2 active species.. The reaction
was initiated through the addition of 5.8 μL sonicated calf thymus DNA (5160 μM in
base pairs) to 294.2 μL of the compound/buffer solution above to give the final
002:CT DNA: NaH2PO4 concentrations of 19.6 μM: 100 μM: 9.8 mM respectively. The
cuvette was placed in the sample holder with the peltier temperature controller set
to 37 oC. Scans were taken periodically until no spectral change was observed.
Triplicate measurements were obtained and curves were fit using one phase
association in Prism software.
4.3 In vitro; GL002 with Guanosine by Uv‐Vis spectroscopy: Experimental
The reaction kinetics were obtained for GL002 with guanosine (Alfa Aesar,
CAS 118‐00‐3) in NaH2PO4 (Sigma) buffer at pH 7.4 at 37 oC using the previously
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mentioned UV‐Vis Spectrophotometer. The instrument was blanked on 3 μL of 1 M
NaH2PO4 (10 mM) and 296.1 μL of deionized water in a small volume cuvette. 0.92
μL of 6.55 mM GL002 (20 μM) was added to the cuvette and an initial scan was
taken. The sample was place under the Dell projector (see Chapter 3.1) under blue
light until no spectral change was observed and photoejection was complete. 9 μL of
a 33.5 mM guanosine stock in DMSO was added to 291 μL of the GL002/NaH2PO4
buffered solution to give GL002: guanosine: NaH2PO4 concentrations of 19.4 μM: 1
mM: 9.7 μM respectively. The cuvette was placed in the sample holder with the
peltier set to 37 oC. Scans were taken periodically until no spectral change was
observed. Triplicate measurements were obtained and the resulting curves were fit
using one phase association in Prism software.
4.4 In Vitro: GL002 with Glutathione
The reaction kinetics were obtained for GL002 and L‐glutathione reduced
(GSH, Sigma, CAS 70‐18‐8) in NaH2PO4 (Sigma) buffer at pH 7.4 at 37 oC using the
previously mentioned UV‐Vis spectrophotometer. The instrument was blanked on 3
μL of 1 M NaH2PO4 (10 mM) and 2498.13 μL of deionized water in a 3 mL cuvette.
0.92 μL of 65.5 mM GL002 (20 μM) was added to the cuvette and an initial scan was
taken. The sample was place under the Dell projector (see Chapter 3.1) under blue
light until no spectral change was observed and photoejection was complete. 480 μL
of 100 mM GSH (16 mM) was added to the mixture and the cuvette was place in the
sample holder with the peltier set to 37 oC. Scans were taken periodically until no
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spectral change was observed. Triplicate measurements were obtained and the
resulting curves were fit using the one phase association in Prism software.
Chapter 5: In Vivo Studies of Light‐Activated Ruthenium Complexes
Dr. David Heidary contributed to this chapter.
Introduction
In vitro results indicate that the synthesized ruthenium complexes are
capable of cross‐linking DNA when photo‐activated. In order to test their in vivo
activity, experiments were carried out on the A549 cell line. A549 or
adenocarcinomic human alveolar basal epithelial cells are a non‐small cell lung
cancer cell line. These adherent cells are responsible for the diffusion of water and
electrolytes across the alveoli of lungs and are cultured as a monolayer. The
immortalized cell line was derived from an explanted tumor of a 58‐year‐old
Caucasian male.17 The lung cancer cell line was chosen as a good model for
photodynamic therapy as the lung is easily accessible with a light source and
photodynamic therapy has been applied with success to lung cancer. 18
Chapter 5.1: A549 Cytotoxicity Assays
Successful photodynamic therapy hinges on the ability to provide cytotoxic
results only when the complexes are activated with light. As described in Chapter
2.2, multiple complexes have been synthesized to examine cell cytotoxicity in search
of a good balance of light and dark toxicity. Due to the numerous compounds
synthesized, this chapter will be divided and discussed as follows: 1) by active
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species a) (Ru(bpy)2 and b) Ru(dmphen)2 and how the in vivo A549 assay results
relate to structural design (see Chapter 2 Design) and photo‐ejection kinetics (see
Chapters 3); 2) in vitro pUC19 DNA results (see Chapter 4.1), with regards to
complexes that crosslink DNA or produce single strand DNA breaks, 3) complexes
with different overall charges, and 4) summary and future work. Complexes that fit
the criteria for each feature will be grouped and discussed. Figures that correspond
to relevant compounds discussed will be included in the text and all cytotoxicity
results will be summarized in a comprehensive table included at the end of the
Chapter. For all experiments, cisplatin was used as a non‐light activated control; it
displays a cytotoxic ratio of one as it displays no noticeable difference in the
presence of light.
Figure 5.1: Cytoxicity curve of cisplatin

To test if only light activated complexes induced cytotoxicity, dark control
experiments were carried out to observe efficacy between the light activated and
unactivated complexes. Cell viability was determined through an ATP luciferase
assay that produces luminescence in the presence of ATP. Detergent lysis was used
to rupture the membrane gaining access to the cellular contents, and the enzyme
luciferase was used to produce luminescence in the presence of ATP. Populations of
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viable and dead cells are quantified through measuring luminescence with the
Tecan plate reader.
1a: Complexes that produce the Ru(bpy)2 backbone
Complexes GL002, 003, 006, 007, 008, 010 have similar backbones and form
the same Ru(bpy)2 active species following activation (Table 5.1).
Table 5.1: Complexes that produce the Ru(bpy)2 active species upon light activation

Complex
Code

A549 Light A549 Dark
Name

(μM)

(μM)

A549
phototherapeutic
ratio

GL002

Ru(bpy)2dmbpy

0.6

250

417

GL003

Ru(bpy)2dmdpq

1.2

250

216

GL006

Ru(bpy)2 ‐3,3’‐dmbpy

30

250

8

GL007

Ru(bpy)2dmphen

0.1

8

80

GL008

Ru(bpy)2bcds

56.3

64.5

1.2

GL010

Ru(bpy)2dmdppz

22

47

2.1

GL014

Ru(bpy)2bc

2.4

9.3

3.9
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Figure 5.2: Example curves for complexes that produce the Ru(bpy)2 active species

It is expected that complexes with similar backbones producing the same
active species should have similar light IC50 values. However, with these complexes
sharing the similar backbone, correlations between the structure and ejection
profiles and the in vitro results can loosely be drawn to explain the potency
observed in the in vivo A549 assay. The general trend is that complexes that are
slower to produce the active species are less effective at cross‐linking DNA and are
less potent compared to their faster ejecting derivatives. The model complex GL002
shows the largest phototherapeutic ratio for this group of complexes of 417. Light
activation of the compound resulted in an IC50 of 0.6 μM while the non‐activated
compound induced cytotoxicity with an IC50 of 250 μM. A similar ratio is observed
with GL003 (216), which has an IC50 of 1.2 μM and dark unactivated IC50 of 250 μM.
The slight decrease in light toxicity of GL003 is attributed to the slower ejection
profile of 60.9 minutes (see Table 3.1). This compliments the two‐fold increases in
the complex’s IC50 in vitro result (see Table 4.1). Complex GL007 is approximately
50 times slower to eject than GL002 (see Table 3.1), but is very potent against the
A549 cell line once photo‐activated (0.1 μM). The ejected dmphen ligand (see Table
3.2) appears to have an effect on the cell line, increasing the dark toxicity similarly
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to what is observed in the Ru(dmphen)2 activated species (see Table 5.2). This may
be attributed to the complexes’ dual mechanism of cross‐linking and producing
single strand breaks as seen in the in vitro results (Table 4.1). Complexes GL008 and
014 are structurally similar and differ only by overall charge through the addition of
the sulfonate groups to GL008 (see Table 2.2). The negatively charged bcds ligand
decreases the overall toxicity toward the cell line. This could be related to the
electrostatic interaction with DNA, raising both the light and dark toxicity to 56.3
and 64.5 μM respectively. This compliments the in vitro results as well (IC50 = 60 μM,
see Table 4.1), possibly indicating that the negatively charged ligand has a
decreased affinity towards DNA. The addition of the bc ligand in complex GL014
(see Table 2.2) has the opposite effect, decreasing both the light and dark toxicity.
This complex is slow to eject at 59.7 minutes (see Table 3.1), but fairly potent when
light activated (2.4 μM), and has considerably more dark toxicity resulting in a
diminished phototherapeutic window of 3.9. GL023 incorporates a similar ligand
and has considerable dark toxicity (see Table 5.2). Diminished potency compared to
GL002 after light activation was observed for complexes GL006 and GL010, with
IC50 values of 30 and 22 μM respectively, despite the fact that they produce the same
active species. This is attributed to their respective slow ejection profiles (t1/2 values
of 230 and >6 hrs respectively; see Table 3.1). On average these complexes are
approximately 150 times slower than GL002 at producing the active species capable
of cross‐linking DNA. As shown in the in vitro results, GL006 has an IC50 of 30 μM at
3 hours under blue light; two fold less effective that GL002 at three hours. The in
vitro result of GL010 is > 60 μM at 3 hours, a difference of four when compared to
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GL002 (see Table 4.1). It is thought that the dark toxicity stems from the extended,
planar dmdppz ligands intercalating nature to bind DNA. This observation is evident
in the three hour in vitro result (see Figure 4.1), as indicated by smearing of the DNA.
For complexes GL006 and 010, irradiation times appear to be very important. To
address the issue of complete conversion to the activated species, optimized
irradiation times should be addressed in future cell assays of slow ejectors to ensure
complete photo‐activation of the complexes.
1b: Complexes that produce the Ru(dmphen)2 backbone
A different approach was evaluated with complexes containing the
Ru(dmphen)2 backbone. Instead of the addition of one sterically hindered ligand
added to the Ru(bpy)2 backbone, steric clash was introduced through the addition
of two sterically hindered ligands in the Ru(dmphen)2 backbone, and then coupled
with various unstrained ligands. Table 5.2 summarizes the complexes that produce
the Ru(dmphen)2 backbone upon light activation.
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Table 5.2: Complexes that produce the Ru(dmphen)2 active species upon light
activation

A549 Light

Complex
Code

Name

(μM)

A549 Dark
(μM)

A549
phototherapeutic
ratio

GL018

Ru(dmphen)28HQ

0.3

0.3

1

GL019

Ru(dmphen)22‐Me‐8HQ

0.6

1.2

2

GL022

Ru(dmphen)2bpy

1.2

24.5

20.4

GL023

Ru(dmphen)2bp

0.2

0.5

2.5

GL039

Ru(dmphen)2dpq

0.8

49.4

61.8

Figure 5.3: Cytoxicity curves of example complexes containing the Ru(dmphen)2
backbone

The Ru(dmphen)2 backbone provided complexes that can be light activated,
but dark toxicity was sacrificed. These complexes have narrow phototherapeutic
windows and behave somewhat like traditional therapeutic metal complexes. The
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quinoline ligands alone are known cytotoxic agents and are discussed in Chapter
2.1.19 GL018 and 019 were synthesized to evaluate the phototherapeutic ratio of the
addition of these cytotoxic ligands with the strained backbone. On average, the
ejection profiles of these complexes are 13 times slower than the model complex
GL002 (see Table 3.1) and produce different photo‐ejection products (see Table 3.2).
GL018 produces a mixture of products upon light activation including the dmphen
ligand (similar to complex GL007, see Table 3.2). This complex is potent in the A549
cell line with an IC50 = 0.3 μM under both dark and light conditions, behaving like a
traditional chemotherapeutic with no phototherapeutic window. The photo‐ejection
products of GL019 are different from 018 (see Table 3.2), ejecting only the 2‐Me‐8‐
HQ ligand, and providing a narrow phototherapeutic window of 2. This complex is
twice as slow as GL018 at producing the active Ru(dmphen)2 species (see Table 3.1)
but maintains potency with a light activated IC50 of 0.6 μM. Both of these complexes
display similar affinity to pUC19 DNA with IC50’s of 30 μM observed in the in vitro
experiments (Table 4.1). Derivatives containing both of these ligands should be
synthesized with negatively charged backbones such as Ru(bpds)2 (see Table 2.1) to
attempt to reduce the dark toxicity issues associated with these complexes. The
complex GL022 ejects in a timely manner (5.4 minutes, see Table 3.1) and ejects a
mixture of products (see Table 3.2). With this combination of ligands, dark toxicity
is diminished, resulting in a phototherapeutic ratio of 20.4. Complex GL023 is
slightly slower to eject at 15.2 minutes (see Table 3.1) and has a phototherapeutic
window of 2.5. The addition of the bp ligand (see Table 2.1) is thought to contribute
to the dark toxicity through increased DNA affinity as seen smearing of the DNA in
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the in vitro gels (see Figure 4.6). A control complex of Ru(bpy)2bp should be
synthesized to observe the dark toxicity associated with the ligand. GL039 has a
wide phototherapeutic window of 61.8 and is quick to eject at 3.2 minutes (see
Table 3.1) producing one active species (Ru(dmphen)dpq, see Table 3.2). This
complex contains a planar, intercalating ligand that has a high affinity to DNA as
seen in the in vitro pUC19 results at three hours (IC50 = 15 μM, see Table 4.1). A light
activated in vivo IC50 value of 0.8 μM is attributed to the ejection of the single
dmphen ligand. The complex Ru(dpq)2dmphen should be synthesized to observe
how the intercalating dpq ligand starting material coupled with the dmphen ligand
interact with DNA and cells.

2) Complexes that produce single strand DNA breaks
Several research groups are synthesizing complexes that produce single
strand breaks through the generation of reactive oxygen species (ROS). These
complexes are described in the literature.5 Three complexes highlighted in this work,
GL004, 005, and 021, also produce in vitro single strand DNA breaks (see Figure 4.5).
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Table 5.3: Complexes that produce in vitro single strand DNA breaks

Complex
Code

A549 Light
Name

(μM)

A549 Dark
(μM)

A549
phototherapeutic
ratio

GL004

Ru(bpy)2phen

40

250

6.3

GL005

Ru(bpds)2dmbpy

1.3

200

154

GL021

Ru(bpy)2dpq

123

123

1

Figure 5.4: Cytoxicity curves of example complexes that produce in vitro single
strand breaks

Of these complexes, GL004 is most efficient at producing the in vitro DNA
breaks followed by GL021, and lastly GL005 (15, 30, and 60 μM respectively, see
Table 4.1). However, there is a disconnect in this design approach based on the
efficiency to produce in vitro single strand breaks and A549 cell cytotoxicity. The
worst single strand breaker, GL005, is shown in Table 5.3 to produce the best
phototherapeutic window of 154 (see cytotoxicity curve in Figure 5.5), followed by
GL004 (6.3) and GL021 (1). GL005 is the only photoactive complex in the group
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with a t1/2 of 0.6 minutes (see Table 3.1). This complex contains the Ru(bpds)2
backbone and carries an overall charge of ‐2 (see Table 2.2), ejecting the dmbpy
ligand upon light activation (see Table 3.2). GL004 contains the phen ligand (see
Table 2.1). This ligand is known to produce ROS, and a similar metal complex,
Cu(phen)2, is used as a standard to produce single strand breaks in the in vitro gel
experiments (see Chapter 4 Experimental).2 GL021 has no distinguishable
phototherapeutic window and contains an intercalating dpq ligand (see Table 2.1).
The planar nature of the dpq ligand enhances DNA affinity leading to dark toxicity.5
This complex intercalates as evident in the smearing of the DNA in the gel and
shows a fairly efficient in vitro IC50 of 30 μM (see Table 4.1) for single strand DNA
breaks. Based on this study, designing complexes based on their ability to produce
single strand breaks does not correlate to in vivo cell cytotoxicity, at least in the
A549 cell line. Additional cell lines should be screened with these complexes to
confirm this analysis.
3) Complexes with different overall charges
The majority of the ruthenium complexes synthesized for this work have the
overall oxidation state of +2. Complexes with overall neutral or negative charges are
of interest due to their low electrostatic attraction with the negatively charged DNA
backbone. Decreased DNA affinity should decrease dark toxicity prior to light
activation. Negatively charged and zero charged complexes such as GL005 and 008
display this property with decreased dark toxicity IC50 values seen below.
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Table 5.4: Complexes with different overall charges to reduce DNA affinity

Complex
Code

A549 Light
Name

(μM)

A549 Dark
(μM)

A549
phototherapeutic
ratio

GL005

Ru(bpds)2dmphen

1.3

250

154

GL008

Ru(bpy)2bcds

56.3

64.5

1.2

Figure 5.5: Cytoxicity curves of complexes that contain different overall charge
states.

The decreased dark toxicity of GL005 (overall charge of ‐2) could stem from
the decreased ionic affinity to the DNA. This complex is potent when light activated
(1.3 μM) and has minimal dark toxicity providing a phototherapeutic window of 154.
A full series of complexes containing this backbone with the dmphen, bp, and bcds
ligands (see Table 2.1) should be synthesized and screened on the A549 cell line to
grasp an understanding of how the overall negative charge affects in vivo results.
Complex GL008 has a net 0 charge, a t1/2 of 12.6 minutes (see Table 3.1), and ejects
the bcds ligand upon light activation (see Table 3.2), producing the Ru(bpy)2 active
species. The negatively charged bcds ligand ejected appears to inhibit in vivo
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toxicity seen in the model complex GL002 and other complexes producing the same
active species (see 5.1a). To see how net 0 charged complexes affect pUC19 DNA and
the A549 cell line, derivatives such as Ru(dmphen)2bpds should be synthesized.
4) Summary and future work
The flexible coordination chemistry (see Chapter 2.1) of ruthenium offers a
unique approach for photodynamic therapy in that DNA affinity can possibly be
reduced or gained based on electrostatics as well as structural features of the
complex. To obtain DNA affinity, modifications to the structure should include
intercalating ligands. Increased dark toxicity can also be obtained through the
addition of bathophen or quinoline ligands and decreased dark toxicity can be
achieved through addition of negatively charged ligands. These functionalities
should be examined in future works. Complexes displaying a red shifted absorption
profile could improve the current PDT capabilities by penetrating deeper lying
tumors.20 Derivatives of complexes containing ligands that display cytotoxic activity
should be coupled with essentially inert backbones. The rich nature of ruthenium
polypyridyl chemistry is well known.21 As such, libraries of complexes can be
synthesized and tested for cell cytoxicity. Combinatorial approaches are known and
can be used to produce and screen large libraries of complexes.6 A comprehensive
table of IC50 results can be found in Table 5.5.
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Table 5.5: In vivo IC50 Values
Complex

Name

Code

A549
light

A549
dark

(μM)

(μM)

A549
ratio

GL001

Cisplatin

1.5

1.5

1

GL002

Ru(bpy)2dmbpy

0.6

250

417

GL003

Ru(bpy)2dmdpq

1.2

250

216

GL004

Ru(bpy)2phen

40

250

6.3

GL005

Ru(bathophendisulfonate)2dmbpy

1.3

250

192

GL006

Ru(bpy)2‐3,3’dmbpy

30

250

8

GL007

Ru(bpy)2dmphen

0.1

8

80

GL008

Ru(bpy)2bathocuprionedisulfonate

56.3

64.5

1.2

GL009

Ru(bpy)2dppz

22

22

1

GL010

Ru(bpy)2dmdppz

22

47

2.1

GL011

Ru(phen)2biquinoline

4.2

22.5

5.4
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Table 5.5: In vivo IC50 Values (cont.)
Complex

Name

Code

a549
light

a549
dark

(μM)

(μM)

a549
ratio

GL013

Ru(bpy)22,2’biq‐3,3’dca

>300

>300

1

GL014

Ru(bpy)2bathocuprione

2.4

9.3

3.9

GL018

Ru(dmphen)28HQ

0.3

0.3

1

GL019

Ru(dmphen)2‐2Me8HQ

0.6

1.2

2

GL021

Ru(bpy)2dpq

123

123

1

GL022

Ru(dmphen)2bpy

1.2

24.5

20.4

GL023

Ru(dmphen)2bathophen 0.2

0.5

2.5

GL039

Ru(dmphen)2dpq

49.4

61.8

0.8

Chapter 5.2: In Vivo A549‐GSH Cell Viability Assay
The A549 lung cancer cell line chosen for this work is known for elevated
glutathione (GSH) levels. A seven‐fold increase was found in the A549 cell line when
compared to normal human lung fibroblast cell line (CCL‐210).14 Normal cellular
levels of GSH range from 1‐30 mM13c The many roles GSH plays in cellular activity
are discussed in Chapter 4.4. Detoxification of antineoplastic agents such as cisplatin
is performed by glutathione S‐transferases that bind the metal and are removed
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from the cell via the ATP dependent GS‐X pump.22 Elevated levels of GSH hinder
cytoxicity of various antineoplastic drugs like melphalan, nitrogen mustard, and
cisplatin.14,23 In addition to decreased cytotoxicity from these common
chemotherapeutics, radiation therapy is also compromised as a result of elevated
GSH levels.24
To ensure the synthesized ruthenium complexes are not deactivated by GSH
and to compare the in vivo effect of GSH on cisplatin and GL002, a dose response of
GSH was performed where the amount of GSH was increased from 0‐16 mM
followed by the addition of the cytotoxic complexes. Cisplatin and GL002
concentrations were held constant at 20 μM. The IC50 of cisplatin in the absence of
GSH was found to be 1.5 μM on A549 cells (see Table 5.5). Cisplatin results are
shown in Figure 5.6a and are consistent with the literature in that cell viability
increases with increasing amounts of GSH. Thus, cisplatin becomes a less efficient
cytotoxic complex, with a GSH IC50 value of 4.3 μM. ~100% of cells are viable at the
top GSH concentration of 16 mM.
GL002 was found to react minimally with GSH in dark experiments and
slowly with GSH upon photo‐activation in vitro, with a t1/2 = 247.6 minutes (see
Figure 4.9b). The A549 IC50 value for the activated complex GL002 is 0.6 μM (Table
5.5). Figure 5.6b shows the GSH titration with photoactivated GL002. Glutathione
seems to enhance cytotoxicity with light activated GL002. No effect was observed
with unactivated GL002. This combination of in vitro and in vivo studies indicate
that the complexes will not be deactivated by GSH both prior to and following light
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activation. In contrast, addition of GSH was found to decrease the binding efficiency
and cytotoxicity of cisplatin. The ability of the synthesized ruthenium complexes to
evade detoxification by GSH while unactivated renders light activation of the
complexes a viable PDT method. Similar in vitro pUC19 gel experiments were
carried out by contributing scientists in our lab with similar results. Future in vivo
A549 light activated studies should be performed to determine the amount of GSH
required for the complete deactivation of photo‐activated GL002. These results
indicate that the ruthenium PDT strategy does not suffer the same inactivation by
biological thiols as platinum agents at physiological concentrations of GSH. Future
studies should focus on the ability of ruthenium agents to avoid alternative
detoxification mechanisms associated with cisplatin resistance.
Figure 5.6: GSH Titration with a) CP and b) GL002
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Chapter 5 Experimental
A549 Growth Inhibition Assays Experimental
A549 cell viability assay
A549 cells were obtained from Dr. Rolf Craven and were grown in Dubelco
Minimum Essential Medium (DMEM), with Earle’s Balanced salt solution (ATCC)
supplemented with 10% (v/v) Serum Supreme (Lonza, Biowhittaker) and 1%
Penicillin/ Streptomycin (Gibco). Cells were maintained at 37 oC in a humidified
atmosphere of 95% air and 5% CO2.
All compounds were screened for cytoxicity in the absence of light and after
light activation. Light and dark toxicity screens were carried out on cell passage
numbers between 7 and 15 in 96 well plates (Costar) in Optimem I Reduced Serum
Medium with 1% Serum Supreme and 1% Penicillin/ Streptomycin (Gibco) in
duplicate. The cells were seeded in the 96 well plates (50 μL) at a density of 1.5 x
103 cells per well and were allowed to adhere for at least four hours before the
addition of compound.
600 μM stock solutions of the ruthenium complexes were prepared in
Optimem with 1% Serum Supreme on a separate 96 well plate. 220 μL were added
to all other wells and 1:3 serial dilutions were performed by transferring 110 μL
down each column of the 96 well plate to give the following compound
concentrations: 600 μM, 200 μM, 67 μM, 22 μM, 7.4 μM, 2.4 μM, 0.8 μM, 0 μM. Once
these dilutions were prepared, 50 μL of the metal solutions were transferred to the
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96 well plate containing 50 μL of cells (1:2 dilution) to give the final ruthenium
concentrations: 300 μM, 100 μM, 33.5 μM, 11 μM, 3.7 μM, 1.2 μM, 0.4 μM, and 0 μM.
During the addition of the ruthenium complexes to the cells, care was taken
to protected the compounds from light. After compound addition, the plates were
covered with aluminum foil to continue their protection from light and incubated at
37 oC with 5% CO2 in a humidified atmosphere for 96 hours. Cell viability was
subsequently measured with the Cell Titer‐Glo Luminescent Cell Viability Assay Kit
(Promega). Viability was measured using a Tecan Spectrafluor Plus plate reader
equipped with Magellan v7.0 software. The luminescent signal, due to the
conversion of luciferin and ATP to oxyluciferin, AMP, and light, was measured after a
five minute incubation of the cells with the cell‐titer glo. During this time complete
cellular lysis occurred allowing for maximal signal with minimal well to well
variability.
Upon overnight incubation of the compounds in the absence of light, light
activation studies were carried out using a 3M overhead projector (model 955) with
an 82 V/ 410 W lamp (Model Osram FXL) fitted with a blue light cutoff filter
(Edmund Optics, part # NT43‐941) and a mirror angled at 45 degrees to reflect the
light downward onto the 96 well plates. The 96 well plates were exposed to blue
light for three minutes and returned to the incubator for 72 hours. Cell viability was
measured with the aforementioned Promega Cell Titer‐Glo Luminescent Cell
Viability Assay Kit. IC50 values were calculated utilizing Prism software with the
curves fit to a Variable Slope, Log(inhibitor) vs. Response equation.
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Chapter 5.2: In Vivo A549‐GSH Cell Viability Assay: Experimental
A549 cells were plated in a similar fashion described in 5.1 at 1500 cells/well.
Identical dark assay conditions as described in Ch. 5.1 Experimental were employed,
but with the addition of L‐glutathione (GSH). Experiments were carried out in
triplicate using Cisplatin and GL002 to determine the effect GSH has on cell viability.
Cisplatin and GL002’s concentrations were held constant, at a concentration of 20
μM, and GSH was subsequently added in dose response at concentrations of 16 μM,
8 μM, 4 μM, 2 μM, 1 μM, 0.5 μM, 0.25 μM, and 0.125 μM. GL002 was light‐activated
after a 12 hour incubation, and viability determined after a total incubation time of
96 hours. The effect of GSH with cisplatin was measured after a 96 hour incubation
with the cells. Viability was measured with the ATP Luciferase assay and the
aforementioned Tecan plate reader at 96 hours. IC50 values were calculated utilizing
Prism software with the curves fit to a Variable Slope, Log(inhibitor) vs. Response
equation.
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